<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>DUAVEE- estrogens, conjugated and bazedoxifene acetate tablet, film coated </strong><br>Wyeth Pharmaceuticals Inc., a subsidiary of Pfizer Inc.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use DUAVEE safely and effectively. See full prescribing information for DUAVEE.<br><br> DUAVEE<span class="Sup">®</span> (conjugated estrogens/bazedoxifene) tablets for oral use<br> Initial U.S. approval: 2013</div>
<div class="Warning"><div>
<h1 class="Warning"><span class="Bold">WARNING: ENDOMETRIAL CANCER, <span class="product-label-link" type="condition" conceptid="134057" conceptname="Disorder of cardiovascular system">CARDIOVASCULAR DISORDERS</span>, AND PROBABLE <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">DEMENTIA</span></span></h1>
<h1 class="Warning"><span class="Bold Italics">See full prescribing information for complete Boxed Warning.</span></h1>
<ul>
<li><span class="Bold">Women taking DUAVEE should not take additional estrogens (<a href="#S5.1">5.1</a>)</span></li>
<li><span class="Bold">There is an increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogens (<a href="#S5.1">5.1</a>, <a href="#S5.3">5.3</a>) </span></li>
<li><span class="Bold">Estrogen therapy should not be used for the prevention of cardiovascular disease or <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> (<a href="#S5.2">5.2</a>, <a href="#S5.4">5.4</a>)</span></li>
<li><span class="Bold">The Women's Health Initiative (WHI) estrogen-alone substudy reported increased risks of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> and <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">deep vein thrombosis</span> (DVT) (<a href="#S5.2">5.2</a>) </span></li>
<li><span class="Bold">The WHI Memory Study (WHIMS) estrogen-alone ancillary study of WHI reported an increased risk of probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> in postmenopausal women 65 years of age and older (<a href="#S5.4">5.4</a>)</span></li>
</ul>
</div></div>
<div></div>
<div class="Warning"><div>
<h1 class="Warning"><span class="Bold">WARNING: ENDOMETRIAL CANCER, <span class="product-label-link" type="condition" conceptid="134057" conceptname="Disorder of cardiovascular system">CARDIOVASCULAR DISORDERS</span>, AND PROBABLE <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">DEMENTIA</span></span></h1>
<h1 class="Warning"><span class="Bold Italics">See full prescribing information for complete Boxed Warning.</span></h1>
<ul>
<li><span class="Bold">Women taking DUAVEE should not take additional estrogens (<a href="#S5.1">5.1</a>)</span></li>
<li><span class="Bold">There is an increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogens (<a href="#S5.1">5.1</a>, <a href="#S5.3">5.3</a>) </span></li>
<li><span class="Bold">Estrogen therapy should not be used for the prevention of cardiovascular disease or <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> (<a href="#S5.2">5.2</a>, <a href="#S5.4">5.4</a>)</span></li>
<li><span class="Bold">The Women's Health Initiative (WHI) estrogen-alone substudy reported increased risks of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> and <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">deep vein thrombosis</span> (DVT) (<a href="#S5.2">5.2</a>) </span></li>
<li><span class="Bold">The WHI Memory Study (WHIMS) estrogen-alone ancillary study of WHI reported an increased risk of probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> in postmenopausal women 65 years of age and older (<a href="#S5.4">5.4</a>)</span></li>
</ul>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">DUAVEE is a combination of conjugated estrogens with an estrogen agonist/antagonist indicated for treatment of the following conditions in women with a uterus: </p>
<ul>
<li> Treatment of moderate to severe vasomotor symptoms associated with <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">menopause</span> (<a href="#S1.1">1.1</a>)</li>
<li> Prevention of postmenopausal <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span> (<a href="#S1.2">1.2</a>)</li>
</ul>
<p class="Highlighta"><span class="Underline">Limitation of Use</span>: DUAVEE should be used for the shortest duration consistent with treatment goals and risks for the individual woman (<a href="#S1.3">1.3</a>) </p>
</div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><ul class="Disc"><li>Take one tablet orally once daily (<a href="#S2">2</a>)</li></ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">Tablet containing conjugated estrogens 0.45 mg and bazedoxifene 20 mg (<a href="#S3">3</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><ul>
<li>Undiagnosed abnormal <span class="product-label-link" type="condition" conceptid="195876" conceptname="Hematometra">uterine bleeding</span> (<a href="#S4">4</a>, <a href="#S5.3">5.3</a>)</li>
<li>Known, suspected, or past history of breast cancer (<a href="#S4">4</a>, <a href="#S5.3">5.3</a>)</li>
<li>Known or suspected estrogen-dependent neoplasia (<a href="#S4">4</a>, <a href="#S5.3">5.3</a>)</li>
<li>Active or past history of <span class="product-label-link" type="condition" conceptid="318775" conceptname="Venous embolism">venous thromboembolism</span> (<a href="#S4">4</a>, <a href="#S5.2">5.2</a>)</li>
<li>Active or past history of arterial <span class="product-label-link" type="condition" conceptid="4159647" conceptname="Thromboembolic disorder">thromboembolism</span> (<a href="#S4">4</a>, <a href="#S5.2">5.2</a>) </li>
<li><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> (<span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>) to estrogens, bazedoxifene, or any ingredients (<a href="#S4">4</a>)</li>
<li>Known <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> or disease (<a href="#S4">4</a>, <a href="#S5.9">5.9</a>, <a href="#S8.7">8.7</a>, <a href="#S12.3">12.3</a>)</li>
<li>Known protein C, protein S, or antithrombin deficiency or other known thrombophilic disorders (<a href="#S4">4</a>)</li>
<li>Pregnancy, women who may become pregnant, and nursing mothers (<a href="#S4">4</a>, <a href="#S8.1">8.1</a>, <a href="#S8.3">8.3</a>)</li>
</ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul>
<li>Women taking DUAVEE should not take progestins, additional estrogens or additional estrogen agonist/antagonists (<a href="#S5.1">5.1</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="134057" conceptname="Disorder of cardiovascular system">Cardiovascular disorders</span>, including <span class="product-label-link" type="condition" conceptid="318775" conceptname="Venous embolism">venous thromboembolism</span>, <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span>, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, and retinal vascular <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span> (<a href="#S5.2">5.2</a>, <a href="#S5.6">5.6</a>)</li>
<li>Malignant neoplasms, including endometrial cancer, breast cancer, and ovarian cancer (<a href="#S5.3">5.3</a>)</li>
<li>Estrogens increase the risk of <span class="product-label-link" type="condition" conceptid="192353" conceptname="Disorder of gallbladder">gallbladder disease</span> (<a href="#S5.5">5.5</a>)</li>
<li>Discontinue estrogen if <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">loss of vision</span>, severe <span class="product-label-link" type="condition" conceptid="440360" conceptname="Pure hyperglyceridemia">hypertriglyceridemia</span> or <span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">cholestatic jaundice</span> occurs (<a href="#S5.6">5.6</a>, <a href="#S5.8">5.8</a>, <a href="#S5.9">5.9</a>)</li>
<li>Monitor thyroid function in women on thyroid replacement therapy (<a href="#S5.10">5.10</a>, <a href="#S5.17">5.17</a>)</li>
</ul></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">In four prospective, randomized, placebo-controlled trials the common adverse reactions (incidence ≥ 5%) were <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">muscle spasms</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>, <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">abdominal pain upper</span>, oropharyngeal <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, and <span class="product-label-link" type="condition" conceptid="24134" conceptname="Neck pain">neck pain</span> (<a href="#S6.1">6.1</a>) </p>
<br><p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Pfizer Inc. at 1-800-438-1985 or FDA at 1-800-FDA-1088 or <span class="Italics">www.fda.gov/medwatch</span>.</span> </p>
</div>
<div><div></div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><ul>
<li>Geriatric Use: DUAVEE was not studied in women aged 75 or older (<a href="#S8.5">8.5</a>, <a href="#S12.3">12.3</a>); use in this population is not recommended (<a href="#S2.7">2.7</a>, <a href="#S8.5">8.5</a>)</li>
<li>An increased risk of probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> in women over 65 years of age was reported in the Women's Health Initiative Memory ancillary studies of the Women's Health Initiative (<a href="#S5.4">5.4</a>, <a href="#S8.5">8.5</a>, <a href="#S14.6">14.6</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>: DUAVEE was not studied in women with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>; use in this population is not recommended (<a href="#S2.6">2.6</a>, <a href="#S8.6">8.6</a>, <a href="#S12.3">12.3</a>)</li>
</ul></div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
</div>
</div>
</div>
</div>
<div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div><div><div></div></div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.</p>
<p class="HighlightsRevision">Revised: 9/2015</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc"><span class="Emphasis">WARNING: ENDOMETRIAL CANCER, <span class="product-label-link" type="condition" conceptid="134057" conceptname="Disorder of cardiovascular system">CARDIOVASCULAR DISORDERS</span>, AND PROBABLE <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">DEMENTIA</span></span></a></h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h2><a href="#section-1.1" class="toc">1.1       Treatment of Moderate to Severe Vasomotor Symptoms Associated with <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">Menopause</span></a></h2>
<h2><a href="#section-1.2" class="toc">1.2       Prevention of Postmenopausal <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">Osteoporosis</span></a></h2>
<h2><a href="#section-1.3" class="toc">1.3       Important Limitations of Use</a></h2>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1         Treatment of Moderate to Severe Vasomotor Symptoms Associated with <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">Menopause</span></a></h2>
<h2><a href="#section-2.2" class="toc">2.2       Prevention of Postmenopausal <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">Osteoporosis</span></a></h2>
<h2><a href="#section-2.3" class="toc">2.3       General Dosing Information</a></h2>
<h2><a href="#section-2.4" class="toc">2.4       Recommendations for Calcium and Vitamin D Supplementation</a></h2>
<h2><a href="#section-2.5" class="toc">2.5       Administration Instructions for Missed Doses</a></h2>
<h2><a href="#section-2.6" class="toc">2.6       Use in Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h2><a href="#section-2.7" class="toc">2.7       Use in the Elderly</a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1       Drugs Containing Progestins, Estrogens or Estrogen Agonist/Antagonists</a></h2>
<h2><a href="#section-5.2" class="toc">5.2       <span class="product-label-link" type="condition" conceptid="134057" conceptname="Disorder of cardiovascular system">Cardiovascular Disorders</span></a></h2>
<h2><a href="#section-5.3" class="toc">5.3       Malignant Neoplasms</a></h2>
<h2><a href="#section-5.4" class="toc">5.4       Probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">Dementia</span></a></h2>
<h2><a href="#section-5.5" class="toc">5.5       <span class="product-label-link" type="condition" conceptid="192353" conceptname="Disorder of gallbladder">Gallbladder Disease</span></a></h2>
<h2><a href="#section-5.6" class="toc">5.6       Visual Abnormalities</a></h2>
<h2><a href="#section-5.7" class="toc">5.7       Elevated Blood Pressure</a></h2>
<h2><a href="#section-5.8" class="toc">5.8       <span class="product-label-link" type="condition" conceptid="440360" conceptname="Pure hyperglyceridemia">Hypertriglyceridemia</span></a></h2>
<h2><a href="#section-5.9" class="toc">5.9       <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span> and Past History of <span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">Cholestatic Jaundice</span></a></h2>
<h2><a href="#section-5.10" class="toc">5.10     <span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">Hypothyroidism</span></a></h2>
<h2><a href="#section-5.11" class="toc">5.11     <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">Fluid Retention</span></a></h2>
<h2><a href="#section-5.12" class="toc">5.12     <span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">Hypocalcemia</span></a></h2>
<h2><a href="#section-5.13" class="toc">5.13     <span class="product-label-link" type="condition" conceptid="4307793" conceptname="Hereditary angioedema">Hereditary Angioedema</span></a></h2>
<h2><a href="#section-5.14" class="toc">5.14     Exacerbation of Other Conditions</a></h2>
<h2><a href="#section-5.15" class="toc">5.15     Premenopausal Women</a></h2>
<h2><a href="#section-5.16" class="toc">5.16	Laboratory Tests</a></h2>
<h2><a href="#section-5.17" class="toc">5.17     Drug-Laboratory Test Interactions</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1       Clinical Trials Experience</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1 Cytochrome P450 (CYP)</a></h2>
<h2><a href="#section-7.2" class="toc">7.2 Uridine Diphosphate Glucuronosyltransferase (UGT)</a></h2>
<h2><a href="#section-7.3" class="toc">7.3 Atorvastatin</a></h2>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.6 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h2><a href="#section-8.6" class="toc">8.7 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h2><a href="#section-8.7" class="toc">8.8 Body <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">Mass</span> Index (BMI)</a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1     Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h2><a href="#section-12.2" class="toc">13.2     Animal Toxicology and/or Pharmacology</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES</a></h1>
<h2><a href="#section-13.1" class="toc">14.1     Treatment of Moderate to Severe Vasomotor Symptoms Associated with <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">Menopause</span> in Women with a Uterus</a></h2>
<h2><a href="#section-13.2" class="toc">14.2     Prevention of Postmenopausal <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">Osteoporosis</span> in Women with a Uterus</a></h2>
<h2><a href="#section-13.3" class="toc">14.3     Effects on the Endometrium</a></h2>
<h2><a href="#section-13.4" class="toc">14.4     Effects on <span class="product-label-link" type="condition" conceptid="195876" conceptname="Hematometra">Uterine Bleeding</span> and Spotting</a></h2>
<h2><a href="#section-13.5" class="toc">14.5     Women's Health Initiative Studies</a></h2>
<h2><a href="#section-13.6" class="toc">14.6     Women's Health Initiative Memory Study</a></h2>
<h1><a href="#section-14" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-15" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<h2><a href="#section-15.1" class="toc">17.1     Instructions for Patients</a></h2>
<h2><a href="#section-15.2" class="toc">17.2     Venous <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">Thromboembolic Events</span></a></h2>
<h2><a href="#section-15.3" class="toc">17.3     Abnormal <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">Vaginal Bleeding</span></a></h2>
<h2><a href="#section-15.4" class="toc">17.4     Possible Serious Adverse Reactions with Estrogen Therapy</a></h2>
<h2><a href="#section-15.5" class="toc">17.5     Possible Less Serious Adverse Reactions with DUAVEE</a></h2>
<h2><a href="#section-15.6" class="toc">17.6     Calcium and Vitamin D Intake</a></h2>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="DLDE"></a><a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="BOX"></a><a name="section-1"></a><p></p>
<h1><span class="Emphasis">WARNING: ENDOMETRIAL CANCER, <span class="product-label-link" type="condition" conceptid="134057" conceptname="Disorder of cardiovascular system">CARDIOVASCULAR DISORDERS</span>, AND PROBABLE <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">DEMENTIA</span></span></h1>
<ul>
<li><span class="Bold">Women taking DUAVEE should not take additional estrogens <span class="Italics">[see <a href="#S5.1">Warnings and Precautions (5.1)</a>]</span></span></li>
<li>
<span class="Bold">There is an increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogens. DUAVEE has been shown to reduce the risk of <span class="product-label-link" type="condition" conceptid="200775" conceptname="Endometrial hyperplasia">endometrial hyperplasia</span>, which may be a precursor to endometrial cancer. Adequate diagnostic measures, including directed or random endometrial sampling when indicated, should be undertaken to rule out malignancy in postmenopausal women with undiagnosed persistent or recurring abnormal genital <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> </span><span class="Bold Italics">[see <a href="#S5.3">Warnings and Precautions (5.3)</a>]</span>
</li>
<li><span class="Bold">Estrogen therapy should not be used for the prevention of cardiovascular disease or <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> <span class="Italics">[see <a href="#S5.2">Warnings and Precautions (5.2</a>, <a href="#S5.4">5.4)</a>]</span></span></li>
<li><span class="Bold">The Women's Health Initiative (WHI) estrogen-alone substudy reported increased risks of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> and <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">deep vein thrombosis</span> (DVT) in postmenopausal women (50 to 79 years of age) during 7.1 years of treatment with daily oral conjugated estrogens (0.625 mg)-alone, relative to placebo <span class="Italics">[see <a href="#S5.2">Warnings and Precautions (5.2)</a>]</span></span></li>
<li><span class="Bold">The WHI Memory Study (WHIMS) estrogen-alone ancillary study of WHI reported an increased risk of probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> in postmenopausal women 65 years of age and older during 5.2 years of treatment with daily conjugated estrogens (0.625 mg)-alone, relative to placebo. It is unknown whether this finding applies to younger postmenopausal women <span class="Italics">[see <a href="#S5.4">Warnings and Precautions (5.4)</a>]</span></span></li>
</ul>
<p class="First"><span class="Bold">In the absence of comparable data, these risks should be assumed to be similar for other doses of conjugated estrogens and other dosage forms of estrogens.</span></p>
<p><span class="Bold">Estrogens should be prescribed at the lowest effective doses and for the shortest duration consistent with treatment goals and risks for the individual woman.</span></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="S1"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<p class="First">DUAVEE is indicated in women with a uterus for:</p>
<div class="Section" data-sectionCode="42229-5">
<a name="S1.1"></a><a name="section-1.1"></a><p></p>
<h2>1.1       Treatment of Moderate to Severe Vasomotor Symptoms Associated with <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">Menopause</span></h2>
<p class="First"></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S1.2"></a><a name="section-1.2"></a><p></p>
<h2>1.2       Prevention of Postmenopausal <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">Osteoporosis</span></h2>
<p class="First"></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S1.3"></a><a name="section-1.3"></a><p></p>
<h2>1.3       Important Limitations of Use</h2>
<ul>
<li>Use DUAVEE for the shortest duration consistent with treatment goals and risks for the individual woman. Postmenopausal women should be re-evaluated periodically as clinically appropriate to determine if treatment is still necessary.</li>
<li>When prescribing solely for the prevention of postmenopausal <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span>, therapy should only be considered for women at significant risk of <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span> and non-estrogen medication should be carefully considered.</li>
</ul>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="S2"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.1"></a><a name="section-2.1"></a><p></p>
<h2>2.1         Treatment of Moderate to Severe Vasomotor Symptoms Associated with <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">Menopause</span></h2>
<p class="First">The recommended dosage is one DUAVEE tablet daily.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.2"></a><a name="section-2.2"></a><p></p>
<h2>2.2       Prevention of Postmenopausal <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">Osteoporosis</span></h2>
<p class="First">The recommended dosage is one DUAVEE tablet daily.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.3"></a><a name="section-2.3"></a><p></p>
<h2>2.3       General Dosing Information</h2>
<p class="First">Take DUAVEE once daily, without regard to meals. Tablets should be swallowed whole.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.4"></a><a name="section-2.4"></a><p></p>
<h2>2.4       Recommendations for Calcium and Vitamin D Supplementation</h2>
<p class="First">Women taking DUAVEE for prevention of postmenopausal <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span> should add supplemental calcium and/or vitamin D to their diet if daily intake is inadequate.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.5"></a><a name="section-2.5"></a><p></p>
<h2>2.5       Administration Instructions for Missed Doses</h2>
<p class="First">If a dose of DUAVEE is missed, instruct patients to take it as soon as remembered unless it is almost time for the next scheduled dose. They should not take two doses at the same time.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.6"></a><a name="section-2.6"></a><p></p>
<h2>2.6       Use in Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">The pharmacokinetics of DUAVEE have not been evaluated in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. Use in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> is not recommended<span class="Italics"> [see <a href="#S8.6">Use in Specific Populations (8.6)</a> and <a href="#S12.3">Clinical Pharmacology (12.3)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.7"></a><a name="section-2.7"></a><p></p>
<h2>2.7       Use in the Elderly</h2>
<p class="First">DUAVEE has not been studied in women over 75 years of age. Use in women over 75 years of age is not recommended.</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="S3"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">DUAVEE (conjugated estrogens/bazedoxifene) tablets, 0.45 mg/20 mg are oval, biconvex, pink tablets, branded with "0.45/20" in black ink on one side.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="S4"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First">DUAVEE is contraindicated in women with any of the following conditions:</p>
<ul>
<li>Undiagnosed abnormal <span class="product-label-link" type="condition" conceptid="195876" conceptname="Hematometra">uterine bleeding</span></li>
<li>Known, suspected, or past history of breast cancer</li>
<li>Known or suspected estrogen-dependent neoplasia</li>
<li>Active deep <span class="product-label-link" type="condition" conceptid="444247" conceptname="Venous thrombosis">venous thrombosis</span>, <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span>, or history of these conditions</li>
<li>Active arterial thromboembolic disease (for example, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>) or history of these conditions</li>
<li><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> (for example, <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>) to estrogens, bazedoxifene, or any ingredients</li>
<li>Known <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> or disease</li>
<li>Known protein C, protein S, or antithrombin deficiency or other known thrombophilic disorders</li>
<li>Pregnancy, women who may become pregnant, and nursing mothers. DUAVEE may cause fetal harm when administered to a pregnant woman. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to a fetus</li>
</ul>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="S5"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.1"></a><a name="section-5.1"></a><p></p>
<h2>5.1       Drugs Containing Progestins, Estrogens or Estrogen Agonist/Antagonists</h2>
<p class="First">DUAVEE contains conjugated estrogens and bazedoxifene, an estrogen agonist/antagonist. Women taking DUAVEE should not take progestins, additional estrogens or additional estrogen agonist/antagonists.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.2"></a><a name="section-5.2"></a><p></p>
<h2>5.2       <span class="product-label-link" type="condition" conceptid="134057" conceptname="Disorder of cardiovascular system">Cardiovascular Disorders</span></h2>
<p class="First">Estrogen agonist/antagonists (including bazedoxifene, a component of DUAVEE) and estrogens individually are known to increase the risk of VTE.</p>
<p>An increased risk of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> and DVT has been reported with estrogen-alone therapy. Should any of these occur or be suspected, DUAVEE should be discontinued immediately.</p>
<p>Risk factors for arterial vascular disease (for example, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus, tobacco use, <span class="product-label-link" type="condition" conceptid="437827" conceptname="Pure hypercholesterolemia">hypercholesterolemia</span>, and <span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">obesity</span>) and/or VTE (for example, personal history or family history of VTE, <span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">obesity</span>, and <span class="product-label-link" type="condition" conceptid="257628" conceptname="Systemic lupus erythematosus">systemic lupus erythematosus</span>) should be managed appropriately.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.2.1"></a><p></p>
<p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Stroke</span></span></p>
<p>In the WHI estrogen-alone substudy, a statistically significant increased risk of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> was reported in women 50 to 79 years of age receiving daily conjugated estrogens (CE) (0.625 mg)-alone compared to women in the same age group receiving placebo (45 versus 33 per 10,000 women-years). The increase in risk was demonstrated in year 1 and persisted <span class="Italics">[see <a href="#S14.5">Clinical Studies (14.5)</a>]</span>.</p>
<p>Subgroup analyses of women 50 to 59 years of age suggest no increased risk of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> for those women receiving conjugated estrogens (0.625 mg)-alone versus those receiving placebo (18 versus 21 per 10,000 women-years).</p>
<p>Should a <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> occur or be suspected, DUAVEE should be discontinued immediately <span class="Italics">[see <a href="#S4">Contraindications (4)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.2.2"></a><p></p>
<p class="First"><span class="Bold">Coronary Heart Disease</span></p>
<p>In the WHI estrogen-alone substudy, no overall effect on coronary heart disease (CHD) events (defined as nonfatal <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, <span class="product-label-link" type="condition" conceptid="4124686" conceptname="Silent myocardial infarction">silent myocardial infarction</span>, or CHD <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>) was reported in women receiving estrogen-alone compared to placebo <span class="Italics">[see <a href="#S14.5">Clinical Studies (14.5)</a>]</span>.</p>
<p>Subgroup analyses of women 50 to 59 years of age suggest a statistically non-significant reduction in CHD events (CE [0.625 mg]-alone compared to placebo) in women with less than 10 years since <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">menopause</span> (8 versus 16 per 10,000 women-years).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.2.3"></a><p></p>
<p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="318775" conceptname="Venous embolism">Venous Thromboembolism</span> (VTE) </span></p>
<p>In the WHI estrogen-alone substudy, the risk of VTE [DVT and <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span> (PE)] was increased for women receiving daily conjugated estrogens (0.625 mg)-alone compared to placebo (30 versus 22 per 10,000 women-years), although only the increased risk of DVT reached statistical significance (23 versus 15 per 10,000 women-years). The increase in VTE risk was demonstrated during the first 2 years <span class="Italics">[see <a href="#S14.5">Clinical Studies (14.5)</a>]</span>.</p>
<p>If feasible, DUAVEE should be discontinued at least 4 to 6 weeks before surgery of the type associated with an increased risk of <span class="product-label-link" type="condition" conceptid="4159647" conceptname="Thromboembolic disorder">thromboembolism</span>, or during periods of prolonged immobilization. Because immobilization increases the risk for venous <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">thromboembolic events</span> independent of therapy, DUAVEE should be discontinued prior to and during prolonged immobilization (e.g., post-surgical recovery, prolonged bed rest) and DUAVEE therapy should be resumed only after the patient is fully ambulatory. In addition, women taking DUAVEE should be advised to move about periodically during travel involving prolonged immobilization.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.3"></a><a name="section-5.3"></a><p></p>
<h2>5.3       Malignant Neoplasms</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.3.1"></a><p></p>
<p class="First"><span class="Bold">Endometrial Cancer</span></p>
<p>An increased risk of endometrial cancer has been reported with the use of unopposed estrogen therapy in women with a uterus. The reported endometrial cancer risk among unopposed estrogen users is about 2 to 12 times greater than in non-users, and appears dependent on duration of treatment and on estrogen dose. Most studies show no significant increased risk associated with use of estrogens for less than 1 year. The greatest risk appears associated with prolonged use, with increased risks of 15- to 24-fold for 5 to 10 years or more of treatment. This risk has been shown to persist for at least 8 to 15 years after estrogen therapy is discontinued.</p>
<p>DUAVEE contains an estrogen agonist/antagonist. This component reduces the risk of <span class="product-label-link" type="condition" conceptid="200775" conceptname="Endometrial hyperplasia">endometrial hyperplasia</span> that can occur with the conjugated estrogens component. <span class="product-label-link" type="condition" conceptid="200775" conceptname="Endometrial hyperplasia">Endometrial hyperplasia</span> may be a precursor to endometrial cancer. Women taking DUAVEE should not take additional estrogens as this may increase the risk of <span class="product-label-link" type="condition" conceptid="200775" conceptname="Endometrial hyperplasia">endometrial hyperplasia</span>.</p>
<p>Clinical surveillance of all women taking DUAVEE is important. Adequate diagnostic measures, including directed or random endometrial sampling when indicated, should be undertaken to rule out malignancy in postmenopausal women with undiagnosed persistent or recurring abnormal genital <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.3.2"></a><p></p>
<p class="First"><span class="Bold">Breast Cancer</span></p>
<p>The most important randomized clinical study providing information about breast cancer in estrogen-alone users is the WHI substudy of daily conjugated estrogens (0.625 mg)-alone. In the WHI estrogen-alone substudy, after an average follow-up of 7.1 years, daily conjugated estrogen (0.625 mg)-alone was not associated with an increased risk of invasive breast cancer (relative risk [RR] 0.80).</p>
<p>The use of estrogen-alone has been reported to result in an increase in abnormal mammograms requiring further evaluation. The effect of treatment with DUAVEE on the risk of breast cancer is unknown.</p>
<p>All women should receive yearly breast examinations by a healthcare provider and perform monthly breast self-examinations. In addition, mammography examinations should be scheduled based on patient age, risk factors, and prior mammogram results.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.3.3"></a><p></p>
<p class="First"><span class="Bold">Ovarian Cancer</span></p>
<p>In some epidemiological studies, the use of estrogen-only products, in particular for 5 or more years, has been associated with an increased risk of ovarian cancer. However, the duration of exposure associated with increased risk is not consistent across all epidemiologic studies, and some report no association. The effect of treatment with DUAVEE on the risk of ovarian cancer is unknown.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.4"></a><a name="section-5.4"></a><p></p>
<h2>5.4       Probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">Dementia</span></h2>
<p class="First">In the WHIMS estrogen-alone ancillary study of WHI, a population of 2,947 hysterectomized women 65 to 79 years of age was randomized to daily CE (0.625 mg)-alone or placebo.</p>
<p>After an average follow-up of 5.2 years, 28 women in the estrogen-alone group and 19 women in the placebo group were diagnosed with probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>. The relative risk of probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> for CE-alone versus placebo was 1.49 (95 percent CI, 0.83–2.66). The absolute risk of probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> for CE-alone versus placebo was 37 versus 25 cases per 10,000 women-years <span class="Italics">[see <a href="#S8.5">Use in Specific Populations (8.5)</a> and <a href="#S14.6">Clinical Studies (14.6)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.5"></a><a name="section-5.5"></a><p></p>
<h2>5.5       <span class="product-label-link" type="condition" conceptid="192353" conceptname="Disorder of gallbladder">Gallbladder Disease</span></h2>
<p class="First">A 2- to 4-fold increase in the risk of <span class="product-label-link" type="condition" conceptid="192353" conceptname="Disorder of gallbladder">gallbladder disease</span> requiring surgery in postmenopausal women receiving estrogens has been reported.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.6"></a><a name="section-5.6"></a><p></p>
<h2>5.6       Visual Abnormalities</h2>
<p class="First">Retinal vascular <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span> has been reported in patients receiving estrogens. Discontinue medication pending examination if there is sudden partial or complete <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">loss of vision</span>, or a sudden onset of <span class="product-label-link" type="condition" conceptid="436700" conceptname="Exophthalmos">proptosis</span>, <span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">diplopia</span>, or <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>. If examination reveals <span class="product-label-link" type="condition" conceptid="4308632" conceptname="Optic disc edema">papilledema</span> or retinal vascular lesions, DUAVEE should be permanently discontinued.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.7"></a><a name="section-5.7"></a><p></p>
<h2>5.7       Elevated Blood Pressure</h2>
<p class="First">In a small number of case reports in women receiving estrogens, substantial increases in blood pressure have been attributed to idiosyncratic reactions to estrogens. In a large, randomized, placebo-controlled clinical study, a generalized effect of estrogens on blood pressure was not seen.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.8"></a><a name="section-5.8"></a><p></p>
<h2>5.8       <span class="product-label-link" type="condition" conceptid="440360" conceptname="Pure hyperglyceridemia">Hypertriglyceridemia</span></h2>
<p class="First">In women with pre-existing <span class="product-label-link" type="condition" conceptid="440360" conceptname="Pure hyperglyceridemia">hypertriglyceridemia</span>, treatment with estrogens may be associated with elevations of plasma triglycerides leading to <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>. Consider discontinuation of DUAVEE if <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span> occurs.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.9"></a><a name="section-5.9"></a><p></p>
<h2>5.9       <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span> and Past History of <span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">Cholestatic Jaundice</span></h2>
<p class="First">DUAVEE has not been studied in women with <span class="product-label-link" type="condition" conceptid="4326594" conceptname="Abnormal liver function">impaired liver function</span> or past history of <span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">cholestatic jaundice</span>.</p>
<p>Estrogens may be poorly metabolized in women with <span class="product-label-link" type="condition" conceptid="4326594" conceptname="Abnormal liver function">impaired liver function</span>.</p>
<p>On average, women with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> treated with bazedoxifene alone showed a 4.3-fold increase in overall exposures compared with controls <span class="Italics">[see <a href="#S8.7">Use in Specific Populations (8.7)</a> and <a href="#S12.3">Clinical Pharmacology (12.3)</a>]</span>.</p>
<p>For women with a history of <span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">cholestatic jaundice</span> associated with past estrogen use or with pregnancy, caution should be exercised; and in the case of recurrence, DUAVEE should be discontinued. Use of DUAVEE in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> is contraindicated <span class="Italics">[see <a href="#S4">Contraindications (4)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.10"></a><a name="section-5.10"></a><p></p>
<h2>5.10     <span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">Hypothyroidism</span></h2>
<p class="First">Estrogen administration leads to increased thyroid-binding globulin (TBG) levels. Women with <span class="product-label-link" type="condition" conceptid="4193309" conceptname="Thyroid function tests normal">normal thyroid function</span> can compensate for the increased TBG by making more thyroid hormone, thus maintaining free T4 and T3 serum concentrations in the normal range. Women dependent on thyroid hormone replacement therapy who are also receiving estrogens may require increased doses of their thyroid replacement therapy. These women should have their thyroid function monitored in order to maintain their free thyroid hormone levels in an acceptable range.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.11"></a><a name="section-5.11"></a><p></p>
<h2>5.11     <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">Fluid Retention</span></h2>
<p class="First">Estrogens may cause some degree of <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span>. Because of this, patients who have conditions that might be influenced by this factor, such as cardiac dysfunction or <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, warrant careful observation when estrogens are prescribed. Use of DUAVEE in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> is not recommended <span class="Italics">[see <a href="#S8.6">Use in Specific Populations (8.6)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.12"></a><a name="section-5.12"></a><p></p>
<h2>5.12     <span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">Hypocalcemia</span></h2>
<p class="First">Estrogen therapy should be used with caution in women with <span class="product-label-link" type="condition" conceptid="140362" conceptname="Hypoparathyroidism">hypoparathyroidism</span> as estrogen-induced <span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">hypocalcemia</span> may occur.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.13"></a><a name="section-5.13"></a><p></p>
<h2>5.13     <span class="product-label-link" type="condition" conceptid="4307793" conceptname="Hereditary angioedema">Hereditary Angioedema</span></h2>
<p class="First">Exogenous estrogens may exacerbate symptoms of <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> in women with <span class="product-label-link" type="condition" conceptid="4307793" conceptname="Hereditary angioedema">hereditary angioedema</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.14"></a><a name="section-5.14"></a><p></p>
<h2>5.14     Exacerbation of Other Conditions</h2>
<p class="First">Estrogens may cause an <span class="product-label-link" type="condition" conceptid="257581" conceptname="Exacerbation of asthma">exacerbation of asthma</span>, <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus, <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span>, <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> or <span class="product-label-link" type="condition" conceptid="4305376" conceptname="Porphyria">porphyria</span>, <span class="product-label-link" type="condition" conceptid="257628" conceptname="Systemic lupus erythematosus">systemic lupus erythematosus</span>, and hepatic <span class="product-label-link" type="condition" conceptid="441818" conceptname="Hemangioma">hemangiomas</span> and should be used with caution in women with these conditions.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.15"></a><a name="section-5.15"></a><p></p>
<h2>5.15     Premenopausal Women</h2>
<p class="First">There is no indication for premenopausal use of DUAVEE. The efficacy and safety of DUAVEE in premenopausal women have not been established, and its use is not recommended.</p>
</div>
<div class="Section" data-sectionCode="34075-2">
<a name="section-5.16"></a><p></p>
<h2>5.16	Laboratory Tests</h2>
<p class="First">Serum follicle stimulating hormone (FSH) and estradiol levels have not been shown to be useful in the management of moderate to severe vasomotor symptoms.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.17"></a><a name="section-5.17"></a><p></p>
<h2>5.17     Drug-Laboratory Test Interactions</h2>
<p class="First">Accelerated <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time, partial thromboplastin time, and platelet aggregation time; increased platelet count; increased factors II, VII antigen, VIII antigen, VIII coagulant activity, IX, X, XII, VII-X complex, II-VII-X complex, and beta-thromboglobulin; decreased levels of antifactor Xa and antithrombin III, decreased antithrombin III activity; increased levels of fibrinogen and fibrinogen activity; increased <span class="product-label-link" type="condition" conceptid="4238994" conceptname="Plasminogen assay">plasminogen</span> antigen and activity.</p>
<p>Increased thyroid-binding globulin (TBG) leading to increased circulating total thyroid hormone, as measured by protein-bound iodine (PBI), T4 levels (by column or by radioimmunoassay), or T3 levels by radioimmunoassay. T3 resin uptake is decreased, reflecting the elevated TBG. Free T4 and free T3 concentrations are unaltered. Women on thyroid replacement therapy may require higher doses of thyroid hormone.</p>
<p>Other binding proteins may be elevated in serum, for example, corticosteroid binding globulin (CBG), sex hormone-binding globulin (SHBG), leading to increased total circulating corticosteroids and sex steroids, respectively. Free hormone concentrations, such as testosterone and estradiol, may be decreased. Other plasma proteins may be increased (angiotensinogen/renin substrate, alpha-1-antitrypsin, <span class="product-label-link" type="condition" conceptid="4294533" conceptname="Ferroxidase">ceruloplasmin</span>).</p>
<p>Increased plasma high-density lipoprotein (HDL) and HDL2 <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> subfraction concentrations, reduced low-density lipoprotein (LDL) <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> concentrations, increased triglyceride levels.</p>
<p>Impaired glucose tolerance.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="S6"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<p class="First">The following adverse reactions are discussed in greater detail in other sections of the label:</p>
<ul>
<li><span class="product-label-link" type="condition" conceptid="134057" conceptname="Disorder of cardiovascular system">Cardiovascular Disorders</span> <span class="Italics">[see <a href="#S5.2">Warnings and Precautions (5.2)</a>]</span>
</li>
<li>Malignant Neoplasms <span class="Italics">[see <a href="#S5.3">Warnings and Precautions (5.3)</a>]</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="192353" conceptname="Disorder of gallbladder">Gallbladder Disease</span> <span class="Italics">[see <a href="#S5.5">Warnings and Precautions (5.5)</a>]</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="440360" conceptname="Pure hyperglyceridemia">Hypertriglyceridemia</span> <span class="Italics">[see <a href="#S5.8">Warnings and Precautions (5.8)</a>]</span>
</li>
</ul>
<div class="Section" data-sectionCode="42229-5">
<a name="S6.1"></a><a name="section-6.1"></a><p></p>
<h2>6.1       Clinical Trials Experience</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.</p>
<p>The safety of conjugated estrogens/bazedoxifene was evaluated in four Phase 3 clinical trials ranging from 12 weeks to 24 months in duration and enrolling 6,210 postmenopausal women age 40 to 75 years (mean age 55 years). A total of 1,224 patients were treated with DUAVEE and 1,069 patients received placebo. Women enrolled in Studies 1 and 2 received calcium (600–1200 mg) and vitamin D (200–400 IU) daily, while women in Studies 3 and 4 received no calcium and vitamin D supplementation as part of the protocol.</p>
<p>The incidence of all-cause mortality was 0.0% in the DUAVEE group and 0.2% in the placebo group. The incidence of serious adverse reactions was 3.5% in the DUAVEE group and 4.8% in the placebo group. The percentage of patients who withdrew from treatment due to adverse reactions was 7.5% in the DUAVEE group and 10.0% in the placebo group. The most common adverse reactions leading to discontinuation were <span class="product-label-link" type="condition" conceptid="4113666" conceptname="Menopausal flushing">hot flush</span>, <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">abdominal pain upper</span>, and <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>.</p>
<p>The most commonly observed adverse reactions (incidence ≥ 5%) more frequently reported in women treated with DUAVEE than placebo are presented in Table 1.</p>
<a name="t1"></a><table width="80%">
<caption><span>Table 1: Adverse Reactions (Incidence ≥ 5%) More Common in the DUAVEE Treatment Group in Placebo-controlled Trials</span></caption>
<col align="left" valign="top" width="34%">
<col align="center" valign="top" width="33%">
<col align="center" valign="top" width="33%">
<thead><tr class="Botrule First Last">
<th class="Lrule Rrule" align="left"></th>
<th class="Rrule" align="center">DUAVEE (N=1224)<br>n (%)</th>
<th class="Rrule" align="center">Placebo (N=1069)<br>n (%)</th>
</tr></thead>
<tbody>
<tr class="Botrule First"><td class="Lrule Rrule" align="left" colspan="3"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal disorders</span></span></td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td class="Rrule" align="center">100 (8)</td>
<td class="Rrule" align="center">58 (5)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
<td class="Rrule" align="center">96 (8)</td>
<td class="Rrule" align="center">57 (5)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span></td>
<td class="Rrule" align="center">84 (7)</td>
<td class="Rrule" align="center">59 (6)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">Abdominal pain upper</span></td>
<td class="Rrule" align="center">81 (7)</td>
<td class="Rrule" align="center">58 (5)</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left" colspan="3"><span class="Bold">Musculoskeletal and <span class="product-label-link" type="condition" conceptid="253549" conceptname="Disorder of connective tissue">connective tissue disorders</span></span></td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">Muscle spasms</span></td>
<td class="Rrule" align="center">110 (9)</td>
<td class="Rrule" align="center">63 (6)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="24134" conceptname="Neck pain">Neck pain</span></td>
<td class="Rrule" align="center">62 (5)</td>
<td class="Rrule" align="center">46 (4)</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left" colspan="3"><span class="Bold"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous system disorders</span></span></td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></td>
<td class="Rrule" align="center">65 (5)</td>
<td class="Rrule" align="center">37 (3)</td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left" colspan="3"><span class="Bold">Respiratory, thoracic, and <span class="product-label-link" type="condition" conceptid="440142" conceptname="Disorder of mediastinum">mediastinal disorders</span></span></td></tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">Oropharyngeal <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span></td>
<td class="Rrule" align="center">80 (7)</td>
<td class="Rrule" align="center">61 (6)</td>
</tr>
</tbody>
</table>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.1"></a><p></p>
<p class="First"><span class="Italics"><span class="product-label-link" type="condition" conceptid="318775" conceptname="Venous embolism">Venous thromboembolism</span></span>: In the clinical studies with DUAVEE, the reporting rates for <span class="product-label-link" type="condition" conceptid="318775" conceptname="Venous embolism">venous thromboembolism</span> (deep <span class="product-label-link" type="condition" conceptid="444247" conceptname="Venous thrombosis">venous thrombosis</span>, <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span>, and <span class="product-label-link" type="condition" conceptid="4187790" conceptname="Thrombosis of retinal vein">retinal vein thrombosis</span>) were low in all treatment groups. Adverse reactions of <span class="product-label-link" type="condition" conceptid="318775" conceptname="Venous embolism">venous thromboembolism</span> were reported in 0.0% of patients treated with DUAVEE and 0.1% of patients treated with placebo. Due to the low rate of events in both groups, it is not possible to conclude that the risk of <span class="product-label-link" type="condition" conceptid="318775" conceptname="Venous embolism">venous thromboembolism</span> with DUAVEE is different from that seen with other estrogen therapies <span class="Italics">[see <a href="#S5.2">Warnings and Precautions (5.2)</a>]</span>.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="S7"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.1"></a><a name="section-7.1"></a><p></p>
<h2>7.1 Cytochrome P450 (CYP)</h2>
<p class="First"><span class="Italics">In vitro</span> and <span class="Italics">in vivo</span> studies have shown that estrogens are metabolized partially by cytochrome P450 3A4 (CYP3A4). Concomitant administration of itraconazole, a strong CYP3A4 inhibitor, with DUAVEE, resulted in increases in bazedoxifene exposure (40%) and, to a lesser extent, conjugated estrogens exposure (9% for baseline-adjusted total estrone, 5% for total equilin), compared to DUAVEE alone <span class="Italics">[see <a href="#S12.3">Pharmacokinetics (12.3)</a>]</span>. Inducers of CYP3A4, such as St. John's Wort (Hypericum perforatum) preparations, phenobarbital, carbamazepine, and rifampin, may reduce plasma concentrations of some estrogens, possibly resulting in a decrease in therapeutic effects and/or changes in the <span class="product-label-link" type="condition" conceptid="195876" conceptname="Hematometra">uterine bleeding</span> profile.</p>
<p>Bazedoxifene does not induce or inhibit the activities of major CYP isoenzymes. <span class="Italics">In vitro</span> data suggest that bazedoxifene is unlikely to interact with co-administered drugs via CYP-mediated metabolism.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.2"></a><a name="section-7.2"></a><p></p>
<h2>7.2 Uridine Diphosphate Glucuronosyltransferase (UGT)</h2>
<p class="First">Bazedoxifene undergoes metabolism by UGT enzymes in the intestinal tract and liver. The metabolism of bazedoxifene may be increased by concomitant use of substances known to induce UGTs, such as rifampin, phenobarbital, carbamazepine, and phenytoin. A reduction in bazedoxifene exposure may be associated with an increase risk of <span class="product-label-link" type="condition" conceptid="200775" conceptname="Endometrial hyperplasia">endometrial hyperplasia</span>. Adequate diagnostic measures, including directed or random endometrial sampling when indicated, should be undertaken to rule out malignancy in postmenopausal women with undiagnosed persistent or recurring abnormal genital <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.3"></a><a name="section-7.3"></a><p></p>
<h2>7.3 Atorvastatin</h2>
<p class="First">Concomitant administration of bazedoxifene (40 mg daily) and atorvastatin (20 mg, single-dose) to healthy postmenopausal women did not affect the pharmacokinetics of bazedoxifene, atorvastatin or its active metabolites.</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="S8"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="S8.1"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.1.1"></a><p></p>
<p class="First">Pregnancy Category X <span class="Italics">[see <a href="#S4">Contraindications (4)</a>]</span></p>
<p>DUAVEE must not be used in women who are or may become pregnant.</p>
<p>No studies were performed on animals to evaluate the effects on reproduction with conjugated estrogens/bazedoxifene.</p>
<p>Administration of bazedoxifene to rats at maternally toxic dosages ≥ 1 mg/kg/day (≥ 0.3 times the human area under the curve (AUC) at the 20 mg dose) resulted in reduced numbers of live fetuses and/or reductions in fetal body weights. No fetal developmental anomalies were observed. In studies conducted with pregnant rabbits treated with bazedoxifene, abortion and an increased incidence of heart (<span class="product-label-link" type="condition" conceptid="434462" conceptname="Ventricular septal defect">ventricular septal defect</span>) and skeletal system (ossification delays, misshapen or misaligned bones, primarily of the spine and skull) anomalies in the fetuses were present at maternally toxic dosages of ≥ 0.5 mg/kg/day (2 times the human AUC at the 20 mg dose).</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="S8.3"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">DUAVEE should not be used by lactating women <span class="Italics">[see <a href="#S4">Contraindications (4)</a>]</span>. It is not known whether this drug is excreted in human milk. Detectable amounts of estrogens have been identified in the milk of mothers receiving conjugated estrogens. Estrogen administration to nursing mothers has been shown to decrease the quantity and quality of the milk.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="S8.4"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">DUAVEE is not indicated for use in children <span class="Italics">[see <a href="#S1">Indications and Usage (1)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="S8.5"></a><a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">DUAVEE is not recommended for use in women greater than 75 years of age <span class="Italics">[see <a href="#S2.7">Dosage and Administration (2.7)</a> and <a href="#S12.3">Clinical Pharmacology 12.3)</a>]</span>.</p>
<p>Of the total number of women in phase 3 clinical studies who received DUAVEE, 4.60% (n=224) were 65 years and over. DUAVEE was not studied in women aged 75 and over. No overall differences in safety or effectiveness were observed between women 65–74 years of age and younger women, and other reported clinical experience has not identified differences in responses between the elderly and younger women, but greater sensitivity of some older women cannot be ruled out.</p>
<p>An increased risk of probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> in women over 65 years of age was reported in the Women's Health Initiative Memory ancillary studies of the Women's Health Initiative using daily conjugated estrogens (0.625 mg) <span class="Italics">[see <a href="#S14.6">Clinical Studies (14.6)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S8.6"></a><a name="section-8.5"></a><p></p>
<h2>8.6 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">DUAVEE is not recommended for use in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> <span class="Italics">[see <a href="#S2.6">Dosage and Administration (2.6)</a> and <a href="#S12.3">Clinical Pharmacology (12.3)</a>]. </span></p>
<p>The pharmacokinetics, safety, and efficacy of DUAVEE have not been evaluated in women with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span><span class="Italics">.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S8.7"></a><a name="section-8.6"></a><p></p>
<h2>8.7 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First">DUAVEE is contraindicated in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> <span class="Italics">[see <a href="#S4">Contraindications (4)</a> and <a href="#S12.3">Clinical Pharmacology (12.3)</a>]. </span></p>
<p>The pharmacokinetics, safety, and efficacy of DUAVEE have not been evaluated in women with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. In a pharmacokinetics study of bazedoxifene 20 mg alone, the C<span class="Sub">max</span> and AUC of bazedoxifene increased 67% and 143%, respectively, in women with mild <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Child Pugh Class A), compared to healthy women. The C<span class="Sub">max</span> and AUC of bazedoxifene increased 32% and 109%, respectively, in women with moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Child Pugh Class B). The C<span class="Sub">max</span> and AUC of bazedoxifene increased 20% and 268%, respectively, in women with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Child Pugh Class C).</p>
<p>No pharmacokinetic studies with conjugated estrogens were conducted in women with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S8.8"></a><a name="section-8.7"></a><p></p>
<h2>8.8 Body <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">Mass</span> Index (BMI)</h2>
<p class="First">Following DUAVEE administration, the systemic exposures of conjugated estrogens and bazedoxifene were lower in obese subjects, compared to non-obese subjects <span class="Italics">[see <a href="#S12.3">Pharmacokinetics (12.3)</a>]</span>.</p>
<p>A single dose of DUAVEE (conjugated estrogens 0.45 mg/bazedoxifene 20 mg) was administered to 12 obese BMI ≥ 30 [mean (SD) = 32.7 (2.7) kg/m<span class="Sup">2</span>] and 12 non-obese BMI &lt; 30 [mean (SD) 25.3 (2.6) kg/m<span class="Sup">2</span>] postmenopausal women. In obese subjects, systemic exposures of total estrone, total equilin, and bazedoxifene were 2%, 32%, and 13% lower, respectively, compared to non-obese subjects.</p>
<p>A greater reduction in bazedoxifene exposure compared to conjugated estrogens may be associated with decreased protection from <span class="product-label-link" type="condition" conceptid="200775" conceptname="Endometrial hyperplasia">endometrial hyperplasia</span>. Monitor and evaluate women with postmenopausal or unexplained genital <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> for possible <span class="product-label-link" type="condition" conceptid="200775" conceptname="Endometrial hyperplasia">endometrial hyperplasia</span> or malignancy <span class="Italics">[see <a href="#S5.3">Warnings and Precautions (5.3)</a>]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="S10"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First">In case of overdosage, there is no specific antidote, and the treatment should be symptomatic.</p>
<p>Symptoms of overdosage of estrogen-containing products in adults and children may include <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="4208409" conceptname="Breast tenderness">breast tenderness</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>/<span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>; <span class="product-label-link" type="condition" conceptid="4161407" conceptname="Withdrawal bleeding">withdrawal bleeding</span> may occur.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="S11"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">DUAVEE (conjugated estrogens/bazedoxifene), contains conjugated estrogens with bazedoxifene, an estrogen agonist/antagonist.</p>
<p>Conjugated estrogens are purified from pregnant mares' urine and consist of the sodium salts of water-soluble estrogen sulfates blended to represent the average composition of material derived from pregnant mares' urine. Conjugated estrogens are a mixture of sodium estrone sulfate and sodium equilin sulfate, and also contain as concomitant components, sodium sulfate conjugates, 17α-dihydroequilin, 17α-estradiol, and 17β-dihydroequilin.</p>
<p>Bazedoxifene is supplied as the acetate salt (bazedoxifene acetate) and has the chemical name 1<span class="Italics">H</span>-Indol-5-ol, 1-[[4-[2-(hexahydro-1<span class="Italics">H</span>-azepin-1-yl) ethoxy]phenyl]methyl]-2-(4-hydroxyphenyl)-3-methyl-, monoacetate. The empirical formula is C<span class="Sub">30</span>H<span class="Sub">34</span>N<span class="Sub">2</span>O<span class="Sub">3</span> ∙ C<span class="Sub">2</span>H<span class="Sub">4</span>O<span class="Sub">2,</span> and the molecular weight is 530.65.</p>
<p>Bazedoxifene acetate is a white to tan powder. The aqueous solubility of bazedoxifene is pH-dependent. Solubility is higher at lower pH. The solubility of bazedoxifene acetate in unbuffered sterile water was measured to be 923 microgramsA/mL at pH 5.4. The following represents the chemical structure of bazedoxifene acetate:</p>
<div class="Figure"><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e1b75458-2e5b-46b9-92c6-fa6daba3770f&amp;name=duavee-01.jpg"></div>
<p>DUAVEE is available for oral administration as tablets containing 0.45 mg of conjugated estrogens with 20 mg of bazedoxifene (equivalent to 22.6 mg of bazedoxifene acetate). Each tablet of DUAVEE contains the following inactive ingredients: calcium phosphate tribasic, hydroxypropyl cellulose, microcrystalline cellulose, powdered cellulose, hypromellose, lactose monohydrate, magnesium stearate, polyethylene glycol, sucrose, ascorbic acid, sucrose palmitic acid ester, hydroxyethylcellulose, titanium dioxide, red iron oxide, yellow iron oxide, black iron oxide, povidone, polydextrose, maltitol, poloxamer 188, propylene glycol, and isopropyl alcohol.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="S12"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="S12.1"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">DUAVEE pairs conjugated estrogens with bazedoxifene. Conjugated estrogens and bazedoxifene function by binding to and activating estrogen receptors (ER) α and β, which vary in proportion from tissue to tissue. Conjugated estrogens are composed of multiple estrogens and are agonists of ER- α and β. Bazedoxifene is an estrogen agonist/antagonist that acts as an agonist in some estrogen-sensitive tissues and an antagonist in others (e.g., uterus). The pairing of conjugated estrogens with bazedoxifene produces a composite effect that is specific to each target tissue. The bazedoxifene component reduces the risk of <span class="product-label-link" type="condition" conceptid="200775" conceptname="Endometrial hyperplasia">endometrial hyperplasia</span> that can occur with the conjugated estrogens component.</p>
<p>Pharmacodynamic studies have not been conducted with DUAVEE.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="S12.3"></a><a name="section-11.2"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2.1"></a><p></p>
<p class="First"><span class="Bold">Absorption</span></p>
<p>Following administration of multiple doses of conjugated estrogens 0.45 mg/bazedoxifene 20 mg to healthy women who were naturally postmenopausal or who had undergone bilateral oophorectomy, the mean steady state pharmacokinetic parameters at Day 10 for conjugated estrogens (baseline adjusted for total estrone) and bazedoxifene are summarized in Table 2.</p>
<a name="t2"></a><table width="85%">
<caption><span>Table 2: Mean ± SD Steady-State Pharmacokinetic Parameters (n=24)</span></caption>
<col align="left" valign="top" width="40%">
<col align="center" valign="top" width="20%">
<col align="center" valign="top" width="20%">
<col align="center" valign="top" width="20%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="left"></th>
<th class="Rrule" align="center">C<span class="Sub">max</span><br>(ng/mL)</th>
<th class="Rrule" align="center">T<span class="Sub">max</span><br>(hr)</th>
<th class="Rrule" align="center">AUCss<br>(ng∙hr/mL)</th>
</tr></thead>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left"><span class="Bold">Baseline-Adjusted Total Estrone</span></td>
<td class="Rrule" align="center">2.6 ± 0.8</td>
<td class="Rrule" align="center">6.5 ± 1.6</td>
<td class="Rrule" align="center">35 ± 12</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left"><span class="Bold">Bazedoxifene</span></td>
<td class="Rrule" align="center">6.9 ± 3.9</td>
<td class="Rrule" align="center">2.5 ± 2.1</td>
<td class="Rrule" align="center">71 ± 34</td>
</tr>
</tbody>
</table>
<p>Results from monotherapy studies with conjugated estrogens or bazedoxifene components of DUAVEE, are noted below:</p>
<p>Conjugated estrogens are soluble in water and are well-absorbed from the gastrointestinal tract after release from the drug formulation.</p>
<p>Bazedoxifene exhibits a linear increase in plasma concentrations for single doses from 0.5 mg up to 120 mg and multiple daily doses from 1 mg to 80 mg. The absolute bioavailability of bazedoxifene is approximately 6%.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2.2"></a><p></p>
<p class="First"><span class="Bold">Food Effect</span></p>
<p>In a single-dose, crossover study in 23 postmenopausal women given conjugated estrogens 0.625 mg/bazedoxifene 20 mg with a high fat/high calorie meal, food increased AUC<span class="Sub">0-inf</span> of bazedoxifene by 25%. The C<span class="Sub">max</span> of bazedoxifene was unchanged.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2.3"></a><p></p>
<p class="First"><span class="Bold">Distribution</span></p>
<p>The distribution of conjugated estrogens and bazedoxifene after administration of DUAVEE has not been studied.</p>
<p>Results from monotherapy studies with conjugated estrogens or bazedoxifene, components of DUAVEE, are noted below:</p>
<p>The distribution of exogenous estrogens is similar to that of endogenous estrogens. Estrogens are widely distributed in the body and are generally found in higher concentrations in the sex hormone target organs. Estrogens circulate in the blood largely bound to <span class="product-label-link" type="condition" conceptid="4206320" conceptname="Sex steroid binding globulin">sex hormone binding globulin</span> (SHBG) and albumin.</p>
<p>Following intravenous (IV) administration of a 3 mg dose of bazedoxifene, the volume of distribution is 14.7 ± 3.9 L/kg. Bazedoxifene is highly bound (98%–99%) to plasma proteins <span class="Italics">in vitro,</span> but does not bind to SHBG.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2.4"></a><p></p>
<p class="First"><span class="Bold">Metabolism</span></p>
<p>The metabolic disposition of conjugated estrogens and bazedoxifene, after administration of DUAVEE, has not been studied.</p>
<p>Results from monotherapy studies with conjugated estrogens or bazedoxifene, components of DUAVEE, are noted below:</p>
<p>Exogenous estrogens are metabolized in the same manner as endogenous estrogens. Circulating estrogens exist in a dynamic equilibrium of metabolic interconversions. 17-β estradiol is converted reversibly to estrone, and both can be converted to estriol, which is the major urinary metabolite. In postmenopausal women, a significant proportion of the circulating estrogens exists as sulfate conjugates, especially estrone sulfate, which serves as a circulating reservoir for the formation of more active estrogens.</p>
<p>The metabolic disposition of bazedoxifene has been determined following oral administration of 20 mg of radiolabeled bazedoxifene. Bazedoxifene is extensively metabolized in women. Glucuronidation is the major metabolic pathway. Little or no cytochrome P450-mediated metabolism is evident. Bazedoxifene-5-glucuronide is the major circulating metabolite. The concentrations of this glucuronide are approximately 10-fold higher than those of unchanged drug in plasma.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2.5"></a><p></p>
<p class="First"><span class="Bold">Excretion</span></p>
<p>After administration of a single dose of conjugated estrogens/bazedoxifene, baseline-adjusted total estrone (representing conjugated estrogens) is eliminated with a half-life of approximately 17 hours. Bazedoxifene is eliminated with a half-life of approximately 30 hours. Steady-state concentrations are achieved by the second week of once-daily administration.</p>
<p>Results from monotherapy studies with conjugated estrogens or bazedoxifene, components of DUAVEE, are noted below:</p>
<p>The conjugated estrogens components, 17β-estradiol, estrone, and estriol are excreted in the urine, along with glucuronide and sulfate conjugates.</p>
<p>The clearance of bazedoxifene is 0.4 ± 0.1 L/h/kg based on intravenous administration. The major route of excretion after oral administration of 20 mg of radiolabeled bazedoxifene is via biliary excretion, followed by elimination in the feces (~85%), with &lt; 1% of the radioactive dose eliminated in the urine. Based on these results, it is expected that bazedoxifene undergoes entero-hepatic recycling from the gut back to the systemic circulation, therefore, some drugs may potentially interfere with bazedoxifene recycling process in the gut by various mechanisms resulting in a decrease in its systemic exposure.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2.6"></a><p></p>
<p class="First"><span class="Bold">Use in Specific Populations</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2.6.1"></a><p></p>
<p class="First"><span class="Italics">Pediatric</span></p>
<p>The pharmacokinetics of conjugated estrogens/bazedoxifene tablets have not been evaluated in a pediatric population <span class="Italics">[see <a href="#S8.4">Use in Specific Populations (8.4)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2.6.2"></a><p></p>
<p class="First"><span class="Italics">Geriatric</span></p>
<p>The effect of age on the pharmacokinetics of conjugated estrogens/bazedoxifene tablets have not been evaluated <span class="Italics">[see <a href="#S8.5">Use in Specific Populations (8.5)</a>]</span>.</p>
<p>No pharmacokinetic studies with conjugated estrogens were conducted in specific populations, including women over 75 years of age.</p>
<p>The pharmacokinetics of a 20 mg single-dose of bazedoxifene, were evaluated in postmenopausal women. On average, compared to women 51 to 64 years of age (n=8), women 65 to 74 years of age (n=8) showed a 1.5-fold increase in AUC, and women ≥ 75 years of age (n=8) showed a 2.6-fold increase in AUC.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2.6.3"></a><p></p>
<p class="First"><span class="Italics"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></span></p>
<p>The pharmacokinetics of conjugated estrogens/bazedoxifene tablets have not been evaluated in women with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> <span class="Italics">[see <a href="#S2.6">Dosage and Administration (2.6)</a> and <a href="#S8.6">Use in Specific Populations (8.6)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2.6.4"></a><p></p>
<p class="First"><span class="Italics"><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></span></p>
<p>The pharmacokinetics of conjugated estrogens/bazedoxifene tablets have not been evaluated in women with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span><span class="Italics"> [see <a href="#S4">Contraindications (4)</a>, <a href="#S5.5">Warnings and Precautions (5.5)</a>, and <a href="#S8.7">Use in Specific Populations (8.7)</a>].</span></p>
<p>No pharmacokinetic studies with conjugated estrogens were conducted in specific populations, including women with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>.</p>
<p>A single dose of bazedoxifene 20 mg was given to fasted, healthy (N=18) and hepatically impaired postmenopausal women. In six mild <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> patients (Child Pugh Class A), C<span class="Sub">max</span> and AUC of bazedoxifene increased 67% and 143%, respectively, compared to healthy subjects. In six moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> patients (Child Pugh Class B), C<span class="Sub">max</span> and AUC of bazedoxifene increased 32% and 109%, respectively, compared to healthy subjects. In six severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> patients (Child Pugh Class C), C<span class="Sub">max</span> and AUC of bazedoxifene increased 20% and 268%, respectively, compared to healthy subjects. Half-life was prolonged from 32 to 50 hrs in patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>, compared to healthy subjects.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2.6.5"></a><p></p>
<p class="First"><span class="Italics">Body <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">Mass</span> Index</span></p>
<p>In a clinical study, a single dose of DUAVEE (conjugated estrogens 0.45 mg/bazedoxifene 20 mg) was administered to 12 obese [mean (SD) BMI = 32.7 (2.7) kg/m<span class="Sup">2</span>] and 12 non-obese [mean (SD) BMI = 25.3 (2.6) kg/m<span class="Sup">2</span>] postmenopausal women. In obese subjects, systemic exposure (AUC0–72) of  total estrone was 2% lower and systemic exposures (AUC0–inf) of  total equilin and bazedoxifene were 32% and 13% lower, respectively, compared to non-obese subjects.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2.7"></a><p></p>
<p class="First"><span class="Bold">Drug Interactions</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2.7.1"></a><p></p>
<p class="First"><span class="Italics Underline">Effect of Co-Administered Drugs on the Pharmacokinetics of Conjugated Estrogens/Bazedoxifene</span></p>
<p>In a drug-drug interaction study, itraconazole 200 mg, a strong CYP3A4 inhibitor, was administered with breakfast to 24 postmenopausal women for 4 days, followed by a fifth dose of itraconazole 200 mg with breakfast and DUAVEE on Day 5 (3 hours after itraconazole). Itraconazole 200 mg was continued for 2 additional days after the co-administration of itraconazole 200 mg and DUAVEE. Following co-administration of DUAVEE and itraconazole, baseline-adjusted total estrone C<span class="Sub">max</span> and AUC0–72 increased 9% and 9%, respectively, total equilin C<span class="Sub">max</span> and AUC0–72 increased 11% and 5%, respectively, and bazedoxifene C<span class="Sub">max</span> and AUC0–inf increased 11% and 40%, respectively, compared to subjects treated with DUAVEE alone.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2.7.2"></a><p></p>
<p class="First"><span class="Italics"><span class="Underline">Effect of Co-Administered Drugs on the Pharmacokinetics of Bazedoxifene</span></span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2.7.2.1"></a><p></p>
<p class="First"><span class="Italics">Conjugated Estrogens</span></p>
<p>Conjugated estrogens 0.625 mg were administered alone for 6 consecutive days prior to the co-administration of a single dose of 20 mg bazedoxifene and conjugated estrogens 0.625 mg in thirty postmenopausal women. Conjugated estrogens 0.625 mg were continued for 2 additional days after the co-administration of bazedoxifene and conjugated estrogens. The C<span class="Sub">max</span> of bazedoxifene increased by 3% and AUC of bazedoxifene decreased by 6%.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2.7.2.2"></a><p></p>
<p class="First"><span class="Italics">Ibuprofen</span></p>
<p>A single dose of ibuprofen 600 mg was given with a bazedoxifene 20 mg capsule in twelve postmenopausal women after an overnight fast. Co-administration of ibuprofen and bazedoxifene increased C<span class="Sub">max</span> and AUC of bazedoxifene by 18% and 7%, respectively.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2.7.2.3"></a><p></p>
<p class="First"><span class="Italics">Atorvastatin</span></p>
<p>Atorvastatin 20 mg was given once with bazedoxifene 40 mg in thirty postmenopausal women. Co-administration of atorvastatin and bazedoxifene decreased C<span class="Sub">max</span> of bazedoxifene by 3% and increased AUC of bazedoxifene by 6%.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2.7.2.4"></a><p></p>
<p class="First"><span class="Italics">Azithromycin</span></p>
<p>Azithromycin 500 mg was given once daily for 8 consecutive days in thirty postmenopausal women. Azithromycin 500 mg and a bazedoxifene 40 mg tablet were co-administered on Day 9. Azithromycin 250 mg administration once daily continued on Days 10 to 13. Co-administration of azithromycin and bazedoxifene increased C<span class="Sub">max</span> of bazedoxifene by 6% and decreased AUC of bazedoxifene by 15%.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2.7.2.5"></a><p></p>
<p class="First"><span class="Italics">Aluminum and Magnesium Hydroxide</span></p>
<p>A single dose of 460 mg aluminum hydroxide and 400 mg magnesium hydroxide was given with a bazedoxifene 40 mg tablet in thirty postmenopausal women after an overnight fast. Co-administration of aluminum/magnesium hydroxide and bazedoxifene decreased C<span class="Sub">max</span> of bazedoxifene by 8% and increased AUC of bazedoxifene by 7%.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2.7.3"></a><p></p>
<p class="First"><span class="Italics"><span class="Underline">Effect of Bazedoxifene on the Pharmacokinetics of Co-Administered Drugs</span></span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2.7.3.1"></a><p></p>
<p class="First"><span class="Italics">Conjugated Estrogens</span></p>
<p>Bazedoxifene 20 mg was administered alone for 8 consecutive days prior to co-administration of a single dose of conjugated estrogens 0.625 mg and bazedoxifene 20 mg in twenty-six postmenopausal women. Bazedoxifene 20 mg was continued for 2 additional days after co-administration of bazedoxifene and conjugated estrogens. The C<span class="Sub">max</span> and AUC of unconjugated estrone increased by 11% and 3%, respectively. The C<span class="Sub">max</span> and AUC of unconjugated equilin increased by 17% and 14%, respectively.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2.7.3.2"></a><p></p>
<p class="First"><span class="Italics">Ibuprofen</span></p>
<p>A single dose of bazedoxifene 20 mg capsule was given with a single dose of ibuprofen 600 mg in twelve fasted, postmenopausal women. Co-administration of bazedoxifene and ibuprofen increased the C<span class="Sub">max</span> of ibuprofen by 6%. The AUC of ibuprofen was unchanged.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2.7.3.3"></a><p></p>
<p class="First"><span class="Italics">Atorvastatin</span></p>
<p>Bazedoxifene 40 mg was given for 8 consecutive days prior to co-administration of bazedoxifene 40 mg and atorvastatin 20 mg. Co-administration of bazedoxifene and atorvastatin decreased C<span class="Sub">max</span> of atorvastatin by 14%. The AUC of atorvastatin was unchanged. The C<span class="Sub">max</span> and AUC of 2-OH atorvastatin were decreased by 18% and 8%, respectively.</p>
</div>
</div>
</div>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="S13"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="S13.1"></a><a name="section-12.1"></a><p></p>
<h2>13.1     Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.1.1"></a><p></p>
<p class="First"><span class="Bold">Carcinogenesis</span></p>
<p>Carcinogenicity studies with conjugated estrogens/bazedoxifene have not been conducted.</p>
<p>Long-term continuous administration of natural and synthetic estrogens in certain animal species increases the frequency of carcinomas of the breast, uterus, cervix, vagina, testis, and liver.</p>
<p>In 6-month oral gavage carcinogenicity studies of bazedoxifene in transgenic Tg.RasH2 mice, there was a drug-related increased incidence of benign, ovarian granulosa-cell tumors in female mice given 150 or 500 mg/kg/day. In a two-year dietary carcinogenicity study of bazedoxifene in rats (administered at 0.003%, 0.01%, 0.03%, or 0.1%) a drug-related marked increased incidence of benign, ovarian granulosa-cell tumors was observed in female rats at concentrations of 0.03% and 0.1%. Systemic exposure (AUC) of bazedoxifene in these groups was 3 and 8 times that observed in postmenopausal women administered 20 mg/day. In male rats, drug-related renal tumors (<span class="product-label-link" type="condition" conceptid="4106411" conceptname="Adenofibroma">adenomas</span> and carcinomas), in the presence of renal toxicity, were observed at all doses tested, which corresponded to exposure ratios of 0.06 to 5 times the clinical AUC at a dose of 20 mg.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.1.2"></a><p></p>
<p class="First"><span class="Bold">Mutagenesis</span></p>
<p>Mutagenicity studies with conjugated estrogens/bazedoxifene have not been conducted.</p>
<p>Bazedoxifene was not genotoxic or mutagenic in a battery of tests, including <span class="Italics">in vitro</span> bacterial reverse mutation assay, <span class="Italics">in vitro</span> mammalian cell forward mutation assay at the thymidine kinase (TK+/-) locus in L5178Y mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> cells, <span class="Italics">in vitro</span> chromosome aberration assay in Chinese hamster ovary (CHO) cells, and <span class="Italics">in vivo</span> mouse micronucleus assay.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.1.3"></a><p></p>
<p class="First"><span class="Bold">Impairment of Fertility</span></p>
<p>Impairment of fertility studies with conjugated estrogens/bazedoxifene have not been conducted.</p>
<p>Female rats were administered daily dosages of 0.3 to 30 mg/kg bazedoxifene (0.03 to 10 times human AUC at the 20 mg dose) prior to and during mating with untreated males. Estrous cycles and fertility were adversely affected in all bazedoxifene-treated female groups.</p>
</div>
</div>
<div class="Section" data-sectionCode="34091-9">
<a name="S13.2"></a><a name="section-12.2"></a><p></p>
<h2>13.2     Animal Toxicology and/or Pharmacology</h2>
<p class="First">In a 12-month study in ovariectomized rats, co-administration of conjugated estrogens (2.5 mg/kg/day) and bazedoxifene (0.1, 0.3, or 1 mg/kg/day) prevented the loss of bone <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span> at the spine, femur, and tibia with concomitant maintenance of biomechanical strength parameters.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="S14"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S14.1"></a><a name="section-13.1"></a><p></p>
<h2>14.1     Treatment of Moderate to Severe Vasomotor Symptoms Associated with <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">Menopause</span> in Women with a Uterus</h2>
<p class="First">The safety and efficacy of DUAVEE as a treatment for moderate to severe vasomotor symptoms associated with <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">menopause</span> was established in a 12-week randomized, double-blind, placebo-controlled study (Study 3). Study 3 enrolled a total of 318 women, age 42–64 (mean age of 53 years), who had at least 7 moderate to severe <span class="product-label-link" type="condition" conceptid="4113666" conceptname="Menopausal flushing">hot flushes</span> per day or at least 50 per week at baseline. The mean number of years since <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">menopause</span> was 4.5 years with all women undergoing natural <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">menopause</span>. A total of 127 women were assigned to DUAVEE and 63 women were assigned to placebo.</p>
<p>In Study 3, DUAVEE significantly reduced the number and severity of moderate to severe <span class="product-label-link" type="condition" conceptid="4113666" conceptname="Menopausal flushing">hot flushes</span>, as measured by the daily severity score, compared with placebo at Weeks 4 and 12. The change from baseline in the number and severity of moderate to severe <span class="product-label-link" type="condition" conceptid="4113666" conceptname="Menopausal flushing">hot flushes</span> observed and the difference from placebo in Study 3 are shown in Table 3.</p>
<table width="90%">
<caption><span>Table 3: Adjusted Mean Change from Baseline in the Average Daily Frequency and Severity of <span class="product-label-link" type="condition" conceptid="4113666" conceptname="Menopausal flushing">Hot Flushes</span> (Study 3)</span></caption>
<col align="left" valign="top" width="20%">
<col align="center" valign="top" width="25%">
<col align="center" valign="top" width="15%">
<col align="center" valign="top" width="25%">
<col align="center" valign="top" width="15%">
<thead>
<tr class="Botrule First">
<th class="Lrule Rrule" align="left"></th>
<th class="Rrule" align="center" colspan="2">Frequency</th>
<th class="Rrule" align="center" colspan="2">Severity</th>
</tr>
<tr class="Last">
<th class="Lrule Rrule" align="left"></th>
<th class="Rrule" align="center">DUAVEE</th>
<th class="Rrule" align="center">Placebo</th>
<th class="Rrule" align="center">DUAVEE</th>
<th class="Rrule" align="center">Placebo</th>
</tr>
</thead>
<tfoot><tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>Change from baseline using ANCOVA model</dd>
<dt><a name="footnote-2" href="#footnote-reference-2">†</a></dt>
<dd>Based on raw data analysis using ANCOVA model: Difference= Treatment + Baseline + Site</dd>
<dt><a name="footnote-3" href="#footnote-reference-3">‡</a></dt>
<dd>p&lt;0.001</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">N</td>
<td class="Rrule" align="center">122</td>
<td class="Rrule" align="center">63</td>
<td class="Rrule" align="center">122</td>
<td class="Rrule" align="center">63</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Baseline</td>
<td class="Rrule" align="center">10.3</td>
<td class="Rrule" align="center">10.5</td>
<td class="Rrule" align="center">2.3</td>
<td class="Rrule" align="center">2.3</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Italics">Week 4</span></td>
<td class="Rrule" align="center" colspan="4"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="right">Mean Change<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a>
</td>
<td class="Rrule" align="center">-5.9</td>
<td class="Rrule" align="center">-2.8</td>
<td class="Rrule" align="center">-0.6</td>
<td class="Rrule" align="center">-0.1</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="right">Treatment Difference<a name="footnote-reference-2" href="#footnote-2" class="Sup">†</a>
</td>
<td class="Rrule" align="center">-3.1 (-4.4, -1.7)<a name="footnote-reference-3" href="#footnote-3" class="Sup">‡</a>
</td>
<td class="Rrule" align="center">--</td>
<td class="Rrule" align="center">-0.5 (-0.7, -0.3)<a href="#footnote-3" class="Sup">‡</a>
</td>
<td class="Rrule" align="center">--</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Italics">Week 12</span></td>
<td class="Rrule" align="center" colspan="4"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="right">Mean Change<a href="#footnote-1" class="Sup">*</a>
</td>
<td class="Rrule" align="center">-7.6</td>
<td class="Rrule" align="center">-4.9</td>
<td class="Rrule" align="center">-0.9</td>
<td class="Rrule" align="center">-0.3</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="right">Treatment Difference<a href="#footnote-2" class="Sup">†</a>
</td>
<td class="Rrule" align="center">-2.7 (-3.8, -1.6)<a href="#footnote-3" class="Sup">‡</a>
</td>
<td class="Rrule" align="center">--</td>
<td class="Rrule" align="center">-0.6 (-0.9, -0.4)<a href="#footnote-3" class="Sup">‡</a>
</td>
<td class="Rrule" align="center">--</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S14.2"></a><a name="section-13.2"></a><p></p>
<h2>14.2     Prevention of Postmenopausal <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">Osteoporosis</span> in Women with a Uterus</h2>
<p class="First">The safety and efficacy of DUAVEE for the prevention of postmenopausal <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span> was demonstrated in Study 1 and Study 2.</p>
<p>Study 1 was a 24-month, double-blind, randomized, placebo- and active-controlled study evaluating the safety and efficacy of multiple combinations of conjugated estrogen/bazedoxifene (including conjugated estrogens 0.45 mg/bazedoxifene 20 mg) compared to placebo. The primary endpoint of the study was the incidence of <span class="product-label-link" type="condition" conceptid="200775" conceptname="Endometrial hyperplasia">endometrial hyperplasia</span> at Year 1. Bone mineral density change at the lumbar spine at Year 2 was the key secondary endpoint, assessed in two subsets of patients (Substudy I and Substudy II). Patients enrolled into Substudy I had to be more than 5 years postmenopausal, have a lumbar spine or total hip T-score of -1 to -2.5, and have at least one additional risk factor for <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span> (e.g., Caucasian race, family history of <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span>, early <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">menopause</span>, thin/small frame, inactive lifestyle, tobacco abuse). Those enrolled into Substudy II had to be 1–5 years postmenopausal with at least one additional risk factor for <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span>. A total of 3,397 women age 40–75 (mean age of 56 years) were enrolled in the overall study. Substudy I enrolled a total of 1,454 women (182 women receiving DUAVEE) with mean baseline T-scores of -1.43 and -1.52 in the DUAVEE and placebo groups, respectively. Substudy II enrolled a total of 861 women (with 111 women receiving DUAVEE) with mean baseline T-scores of -0.81 and -0.94 in the DUAVEE and placebo groups, respectively. Women also took calcium (600–1200 mg) and vitamin D (200–400 IU) daily.</p>
<p>In these substudies, treatment with DUAVEE significantly increased lumbar spine bone mineral density (BMD) at 24 months compared to placebo in both groups of postmenopausal women (Table 4).</p>
<a name="t4"></a><table width="80%">
<caption><span>Table 4: Lumbar Spine Bone Mineral Density Results at 24 Months (Study 1)</span></caption>
<col align="left" valign="top" width="50%">
<col align="center" valign="top" width="35%">
<col align="center" valign="top" width="15%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="left"></th>
<th class="Rrule" align="center">DUAVEE</th>
<th class="Rrule" align="center">Placebo</th>
</tr></thead>
<tfoot>
<tr class="First Last"><td align="left" colspan="3">** Adjusted mean changes, confidence intervals, and p-values based on an ANCOVA model with treatment and region (U.S. or non-U.S.) as factors and baseline BMD value and years since <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">menopause</span> as covariates using the Modified Intention to Treat population with Last Observation Carried Forward. Study 1 excludes those subjects with missing source documentation.</td></tr>
<tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-4" href="#footnote-reference-4">*</a></dt>
<dd>p-value &lt; 0.001</dd>
</dl></td></tr>
</tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left"><span class="Bold">Between 1 and 5 Years Postmenopausal</span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">N</td>
<td class="Rrule" align="center">95</td>
<td class="Rrule" align="center">95</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">% Mean Change</td>
<td class="Rrule" align="center">1.72</td>
<td class="Rrule" align="center">-1.90</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">Difference from Placebo (95% C.I.)</td>
<td class="Rrule" align="center">3.62 (2.64, 4.60)<a name="footnote-reference-4" href="#footnote-4" class="Sup">*</a>
</td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule Toprule" align="left"><span class="Bold">More Than 5 Years Postmenopausal</span></td>
<td class="Rrule Toprule" align="center"></td>
<td class="Rrule Toprule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">N</td>
<td class="Rrule" align="center">155</td>
<td class="Rrule" align="center">151</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">% Mean Change</td>
<td class="Rrule" align="center">1.64</td>
<td class="Rrule" align="center">-1.47</td>
</tr>
<tr class="Botrule Last">
<td class="Lrule Rrule" align="left">Difference from Placebo (95% C.I.)</td>
<td class="Rrule" align="center">3.11 (2.29, 3.93)<a href="#footnote-4" class="Sup">*</a>
</td>
<td class="Rrule" align="center">–</td>
</tr>
</tbody>
</table>
<p>In Study 1, treatment with DUAVEE also significantly increased total hip BMD. The treatment difference (or difference from placebo) in total hip BMD at 24 months was 1.96% (DUAVEE minus placebo) in women who had been postmenopausal between 1 and 5 years and 1.73% (DUAVEE minus placebo) in women who had been postmenopausal for more than 5 years.</p>
<p>Study 2 was a 12-month, double-blind, randomized, placebo- and active-controlled study. The primary endpoint was the incidence of <span class="product-label-link" type="condition" conceptid="200775" conceptname="Endometrial hyperplasia">endometrial hyperplasia</span> at 12 months. The prevention of <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span> was assessed in a substudy that enrolled women (n=590) who were less than 5 years postmenopausal (mean 2.5 years). The mean baseline T-score in the substudy was -0.91 in the DUAVEE group and -0.95 in the placebo group. The mean age of women (n=135) taking DUAVEE was 53 years (range 46-60 years). Women also took calcium (600 mg) and vitamin D (400 IU) daily.</p>
<p>In Study 2, treatment with DUAVEE significantly increased mean lumbar spine BMD (treatment difference, 1.51%), at 12 months compared to placebo in women who had been postmenopausal between 1 and 5 years. Treatment with DUAVEE also increased total hip BMD. The treatment difference in total hip BMD at 12 months was 1.21%.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S14.3"></a><a name="section-13.3"></a><p></p>
<h2>14.3     Effects on the Endometrium</h2>
<p class="First">Effects of DUAVEE on <span class="product-label-link" type="condition" conceptid="200775" conceptname="Endometrial hyperplasia">endometrial hyperplasia</span> and endometrial malignancy were assessed in Study 1 and Study 2. The Efficacy Evaluable population included patients who had taken at least one dose of DUAVEE, had baseline and post baseline endometrial biopsies, or had been diagnosed with <span class="product-label-link" type="condition" conceptid="4296894" conceptname="Hyperplasia">hyperplasia</span>. By endometrial biopsy, the incidence of <span class="product-label-link" type="condition" conceptid="200775" conceptname="Endometrial hyperplasia">endometrial hyperplasia</span> or malignancy for DUAVEE was below 1% in both studies (see <a href="#t5">Table 5</a>).</p>
<a name="t5"></a><table width="90%">
<caption><span>Table 5: Incidence of <span class="product-label-link" type="condition" conceptid="200775" conceptname="Endometrial hyperplasia">Endometrial Hyperplasia</span> or Malignancy at Month 12 and Month 24</span></caption>
<col align="center" valign="middle" width="25%">
<col align="center" valign="middle" width="15%">
<col align="center" valign="middle" width="18%">
<col align="center" valign="middle" width="12%">
<col align="center" valign="middle" width="18%">
<col align="center" valign="middle" width="12%">
<thead>
<tr class="Botrule First">
<th class="Lrule Rrule" align="center"></th>
<th class="Rrule" align="center"></th>
<th class="Rrule" align="center" colspan="2">STUDY 1<a name="footnote-reference-5" href="#footnote-5" class="Sup">*</a>
</th>
<th class="Rrule" align="center" colspan="2">STUDY 2<a href="#footnote-5" class="Sup">*</a>
</th>
</tr>
<tr class="Last" valign="top">
<th class="Lrule Rrule" align="left">Treatment Group</th>
<th class="Rrule" align="center">Month</th>
<th class="Rrule" align="center">% (n/N)</th>
<th class="Rrule" align="center">1 – Sided 95% UL</th>
<th class="Rrule" align="center">% (n/N)</th>
<th class="Rrule" align="center">1 – Sided 95% UL</th>
</tr>
</thead>
<tfoot>
<tr class="First Last"><td align="left" colspan="6">UL = Upper limit</td></tr>
<tr><td colspan="6" align="left"><dl class="Footnote">
<dt><a name="footnote-5" href="#footnote-reference-5">*</a></dt>
<dd>Efficacy Evaluable population</dd>
</dl></td></tr>
</tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="center" rowspan="2"><span class="Bold">DUAVEE</span></td>
<td class="Rrule" align="center">12</td>
<td class="Rrule" align="center">0.00% (0/336)</td>
<td class="Rrule" align="center">0.89</td>
<td class="Rrule" align="center">0.30% (1/335)</td>
<td class="Rrule" align="center">1.41</td>
</tr>
<tr class="Botrule Last">
<td class="Rrule" align="center">24</td>
<td class="Rrule" align="center">0.68% (2/294)</td>
<td class="Rrule" align="center">2.13</td>
<td class="Rrule" align="center">--</td>
<td class="Rrule" align="center">--</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S14.4"></a><a name="section-13.4"></a><p></p>
<h2>14.4     Effects on <span class="product-label-link" type="condition" conceptid="195876" conceptname="Hematometra">Uterine Bleeding</span> and Spotting</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="195876" conceptname="Hematometra">Uterine bleeding</span> or spotting were evaluated in two clinical studies (Studies 1 and 2) by daily diary. In Study 1, cumulative <span class="product-label-link" type="condition" conceptid="443800" conceptname="Amenorrhea">amenorrhea</span> at Year 1 was 83% in women treated with DUAVEE and 85% in women who received placebo. In Study 2, cumulative <span class="product-label-link" type="condition" conceptid="443800" conceptname="Amenorrhea">amenorrhea</span> at Year 1 was 88% in women treated with DUAVEE and 84% in women who received placebo.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S14.5"></a><a name="section-13.5"></a><p></p>
<h2>14.5     Women's Health Initiative Studies</h2>
<p class="First">The WHI enrolled approximately 11,000 predominantly healthy postmenopausal women to assess the risks and benefits of daily oral conjugated estrogens 0.625 mg compared to placebo in the prevention of certain chronic diseases. The primary endpoint was the incidence of CHD (defined as nonfatal MI, silent MI and CHD <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>), with invasive breast cancer as the primary adverse outcome. A "global index" included the earliest occurrence of CHD, invasive breast cancer, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, PE, colorectal cancer, <span class="product-label-link" type="condition" conceptid="4138412" conceptname="Fracture of proximal end of femur">hip fracture</span>, or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> due to other cause. These substudies did not evaluate the effects of conjugated estrogens on <span class="product-label-link" type="condition" conceptid="439082" conceptname="Menopausal syndrome">menopausal symptoms</span>.</p>
<p>The WHI estrogen-alone substudy was stopped early because an increased risk of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> was observed, and it was deemed that no further information would be obtained regarding the risks and benefits of estrogen-alone in predetermined primary endpoints.</p>
<p>Results of the estrogen-alone substudy, which included 10,739 women (average 63 years of age, range 50 to 79; 75.3 percent White, 15.1 percent Black, 6.1 percent Hispanic, 3.6 percent Other), after an average follow- up of 7.1 years are presented in Table 6.</p>
<a name="t6"></a><table width="85%">
<caption><span>Table 6: Relative and Absolute Risk Seen in the Estrogen Alone Substudy of WHI<a name="footnote-reference-6" href="#footnote-6" class="Sup">*</a></span></caption>
<col align="left" valign="middle" width="30%">
<col align="center" valign="middle" width="30%">
<col align="center" valign="middle" width="20%">
<col align="center" valign="middle" width="20%">
<thead>
<tr class="Botrule First">
<th class="Lrule Rrule" align="left" rowspan="2">Event</th>
<th class="Rrule" align="center" rowspan="2">Relative Risk<br>CE vs. Placebo<br>(95% nCI<a name="footnote-reference-7" href="#footnote-7" class="Sup">†</a>)</th>
<th class="Rrule" align="center">CE<br>n = 5,310</th>
<th class="Rrule" align="center">Placebo<br>N = 5,429</th>
</tr>
<tr class="Last"><th class="Rrule" align="center" colspan="2">Absolute Risk per 10,000 Women-Years</th></tr>
</thead>
<tfoot><tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-6" href="#footnote-reference-6">*</a></dt>
<dd>Adapted from numerous WHI publications. WHI publications can be viewed at www.nhlbi.nih.gov/whi.</dd>
<dt><a name="footnote-7" href="#footnote-reference-7">†</a></dt>
<dd>Nominal confidence intervals unadjusted for multiple looks and multiple comparisons.</dd>
<dt><a name="footnote-8" href="#footnote-reference-8">‡</a></dt>
<dd>Results are based on centrally adjudicated data for an average follow-up of 7.1 years.</dd>
<dt><a name="footnote-9" href="#footnote-reference-9">§</a></dt>
<dd>Not included in "global index".</dd>
<dt><a name="footnote-10" href="#footnote-reference-10">¶</a></dt>
<dd>Results are based on an average follow-up of 6.8 years.</dd>
<dt><a name="footnote-11" href="#footnote-reference-11">#</a></dt>
<dd>All <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span>, except from breast or colorectal cancer, definite or probable CHD, PE, or cerebrovascular disease.</dd>
<dt><a name="footnote-12" href="#footnote-reference-12">Þ</a></dt>
<dd>A subset of the events was combined in a "global index", defined as the earliest occurrence of CHD events, invasive breast cancer, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, PE, endometrial cancer, colorectal cancer, <span class="product-label-link" type="condition" conceptid="4138412" conceptname="Fracture of proximal end of femur">hip fracture</span>, or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> due to other causes.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Lrule Rrule" align="left">CHD events<a name="footnote-reference-8" href="#footnote-8" class="Sup">‡</a>
</td>
<td class="Rrule" align="center">0.95 (0.78–1.16)</td>
<td class="Rrule" align="center">54</td>
<td class="Rrule" align="center">57</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">
<span class="Italics">Non-fatal </span><span class="Italics">MI<a href="#footnote-8" class="Sup">‡</a></span>
</td>
<td class="Rrule" align="center"><span class="Italics">0.91 (0.73–1.14)</span></td>
<td class="Rrule" align="center"><span class="Italics">40</span></td>
<td class="Rrule" align="center"><span class="Italics">43</span></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Italics">CHD <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span><a href="#footnote-8" class="Sup">‡</a></span></td>
<td class="Rrule" align="center"><span class="Italics">1.01 (0.71–1.43)</span></td>
<td class="Rrule" align="center"><span class="Italics">16</span></td>
<td class="Rrule" align="center"><span class="Italics">16</span></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">All <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">strokes</span><a href="#footnote-8" class="Sup">‡</a>
</td>
<td class="Rrule" align="center">1.33 (1.15–1.68)</td>
<td class="Rrule" align="center">45</td>
<td class="Rrule" align="center">33</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Italics"><span class="product-label-link" type="condition" conceptid="4310996" conceptname="Ischemic stroke">Ischemic stroke</span><a href="#footnote-8" class="Sup">‡</a></span></td>
<td class="Rrule" align="center"><span class="Italics">1.55 (1.19–2.01)</span></td>
<td class="Rrule" align="center"><span class="Italics">38</span></td>
<td class="Rrule" align="center"><span class="Italics">25</span></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">Deep vein thrombosis</span><a href="#footnote-8" class="Sup">‡</a><span class="Sup">,</span><a name="footnote-reference-9" href="#footnote-9" class="Sup">§</a>
</td>
<td class="Rrule" align="center">1.47 (1.06–2.06)</td>
<td class="Rrule" align="center">23</td>
<td class="Rrule" align="center">15</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">Pulmonary embolism</span><a href="#footnote-8" class="Sup">‡</a>
</td>
<td class="Rrule" align="center">1.37 (0.90–2.07)</td>
<td class="Rrule" align="center">14</td>
<td class="Rrule" align="center">10</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Invasive breast cancer<a href="#footnote-8" class="Sup">‡</a>
</td>
<td class="Rrule" align="center">0.80 (0.62–1.04)</td>
<td class="Rrule" align="center">28</td>
<td class="Rrule" align="center">34</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Colorectal cancer<a name="footnote-reference-10" href="#footnote-10" class="Sup">¶</a>
</td>
<td class="Rrule" align="center">1.08 (0.75–1.55)</td>
<td class="Rrule" align="center">17</td>
<td class="Rrule" align="center">16</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4138412" conceptname="Fracture of proximal end of femur">Hip fracture</span><a href="#footnote-8" class="Sup">‡</a>
</td>
<td class="Rrule" align="center">0.65 (0.45–0.94)</td>
<td class="Rrule" align="center">12</td>
<td class="Rrule" align="center">19</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4066995" conceptname="Fracture of vertebral column with spinal cord injury">Vertebral fractures</span><a href="#footnote-8" class="Sup">‡</a><span class="Sup">,</span><a href="#footnote-9" class="Sup">§</a>
</td>
<td class="Rrule" align="center">0.64 (0.44–0.93)</td>
<td class="Rrule" align="center">11</td>
<td class="Rrule" align="center">18</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Lower arm/wrist <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fractures</span><a href="#footnote-8" class="Sup">‡</a><span class="Sup">,</span><a href="#footnote-9" class="Sup">§</a>
</td>
<td class="Rrule" align="center">0.58 (0.47–0.72)</td>
<td class="Rrule" align="center">35</td>
<td class="Rrule" align="center">59</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Total <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fractures</span><a href="#footnote-8" class="Sup">‡</a><span class="Sup">,</span><a href="#footnote-9" class="Sup">§</a>
</td>
<td class="Rrule" align="center">0.71 (0.64–0.80)</td>
<td class="Rrule" align="center">144</td>
<td class="Rrule" align="center">197</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span> due to other causes<a href="#footnote-10" class="Sup">¶</a><span class="Sup">,</span><a name="footnote-reference-11" href="#footnote-11" class="Sup">#</a>
</td>
<td class="Rrule" align="center">1.08 (0.88–1.32)</td>
<td class="Rrule" align="center">53</td>
<td class="Rrule" align="center">50</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Overall mortality<a href="#footnote-8" class="Sup">‡</a><span class="Sup">,</span><a href="#footnote-9" class="Sup">§</a>
</td>
<td class="Rrule" align="center">1.04 (0.88–1.22)</td>
<td class="Rrule" align="center">79</td>
<td class="Rrule" align="center">75</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">Global Index<a name="footnote-reference-12" href="#footnote-12" class="Sup">Þ</a>
</td>
<td class="Rrule" align="center">1.02 (0.92–1.13)</td>
<td class="Rrule" align="center">206</td>
<td class="Rrule" align="center">201</td>
</tr>
</tbody>
</table>
<p>For those outcomes included in the WHI "global index" that reached statistical significance, the absolute excess risk per 10,000 women-years in the group treated with CE-alone was 12 more <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">strokes</span>, while the absolute risk reduction per 10,000 women-years was 7 fewer <span class="product-label-link" type="condition" conceptid="4138412" conceptname="Fracture of proximal end of femur">hip fractures</span>. The absolute excess risk of events included in the "global index" was a non-significant 5 events per 10,000 women-years. There was no difference between the groups in terms of all-cause mortality.</p>
<p>No overall difference for primary CHD events (nonfatal MI, silent MI and CHD <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>) and invasive breast cancer incidence in women receiving conjugated estrogens-alone compared to placebo was reported in final centrally adjudicated results from the estrogen-alone substudy, after an average follow-up of 7.1 years.</p>
<p>Centrally adjudicated results for <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> events from the estrogen-alone substudy, after an average follow-up of 7.1 years, reported no significant differences in distribution of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> subtype or severity, including fatal <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">strokes</span>, in women receiving conjugated estrogens-alone compared to placebo. Estrogen-alone increased the risk for <span class="product-label-link" type="condition" conceptid="4310996" conceptname="Ischemic stroke">ischemic stroke</span>, and this excess risk was present in all subgroups of women examined.</p>
<p>Timing of the initiation of estrogen-alone therapy relative to the start of <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">menopause</span> may affect the overall risk benefit profile. The WHI estrogen-alone substudy, stratified by age, showed in women 50 to 59 years of age a non-significant trend toward reduced risk for CHD [hazard ratio (HR) 0.63 (95 percent CI, 0.36–1.09)] and overall mortality [HR 0.71 (95 percent CI, 0.46–1.11)].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S14.6"></a><a name="section-13.6"></a><p></p>
<h2>14.6     Women's Health Initiative Memory Study</h2>
<p class="First">The WHIMS estrogen-alone ancillary study of WHI enrolled 2,947 predominantly healthy hysterectomized postmenopausal women 65 to 79 years of age (45 percent were 65 to 69 years of age, 36 percent were 70 to 74 years of age, and 19 percent were 75 years of age and older) to evaluate the effects of daily conjugated estrogens (0.625 mg)-alone on the incidence of probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> (primary outcome) compared to placebo.</p>
<p>After an average follow-up of 5.2 years, the relative risk of probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> for conjugated estrogens-alone versus placebo was 1.49 (95 percent CI, 0.83–2.66). The absolute risk of probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> for conjugated estrogens-alone versus placebo was 37 versus 25 cases per 10,000 women-years. Probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> as defined in this study included Alzheimer's disease (AD), <span class="product-label-link" type="condition" conceptid="379778" conceptname="Multi-infarct dementia">vascular dementia</span> (VaD) and mixed type (having features of both AD and VaD). The most common classification of probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> in the treatment group and the placebo group was AD. Since the ancillary study was conducted in women 65 to 79 years of age, it is unknown whether these findings apply to younger postmenopausal women <span class="Italics">[see <a href="#S5.4">Warnings and Precautions (5.4)</a> and <a href="#S8.5">Use in Specific Populations (8.5)</a>]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="S16"></a><a name="section-14"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">DUAVEE tablets contain 0.45 mg conjugated estrogens and 20 mg bazedoxifene. The tablets are oval, biconvex, and pink, branded with "0.45/20" in black ink on one side.</p>
<p>DUAVEE<span class="Sup">®</span> tablets are supplied as follows:</p>
<table width="80%">
<col align="left" valign="top" width="34%">
<col align="center" valign="top" width="33%">
<col align="center" valign="top" width="33%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="left"></th>
<th class="Rrule" align="center">Package</th>
<th class="Rrule" align="center">NDC number</th>
</tr></thead>
<tbody><tr class="First Last">
<td class="Lrule Rrule" align="left">Conjugated estrogens 0.45 mg/bazedoxifene 20 mg</td>
<td class="Rrule" align="center">2 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span> of 15 tablets each</td>
<td class="Rrule" align="center">NDC 0008-1123-12</td>
</tr></tbody>
</table>
<div class="Section" data-sectionCode="44425-7">
<a name="section-14.1"></a><p></p>
<p class="First"><span class="Bold">Storage</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-14.1.1"></a><p></p>
<p class="First"><span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blisters</span></p>
<p>DUAVEE tablets should be stored at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F). See USP Controlled Room Temperature. Dispense product in the original package. Tablets should not be removed from <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span> until immediately before use. Protect from moisture. After opening foil pouch, product must be used within 60 days.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="S17"></a><a name="section-15"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First">See <a href="#PPI">FDA-approved patient labeling (Patient Information)</a>.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="S17.1"></a><a name="section-15.1"></a><p></p>
<h2>17.1     Instructions for Patients</h2>
<ul class="Disc">
<li>Keep DUAVEE in the original container   to protect from moisture. Do not place DUAVEE in pill boxes or pill   organizers.</li>
<li>If more than one <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> package   is dispensed to the patient, instruct them to open one foil pouch at a   time.</li>
<li>Instruct patient to record the   date the <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> package is opened in the space provided on the <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span>   package label. Do not use if the <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> package has been open more than   60 days.</li>
<li>Instruct patient to remove only   one tablet from the <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> package at the time of use.</li>
</ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S17.2"></a><a name="section-15.2"></a><p></p>
<h2>17.2     Venous <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">Thromboembolic Events</span></h2>
<p class="First">Advise patients to immediately report to their physician any signs or symptoms related to <span class="product-label-link" type="condition" conceptid="444247" conceptname="Venous thrombosis">venous thrombosis</span> and <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">thromboembolic events</span> <span class="Italics">[see <a href="#S5.2">Warnings and Precautions (5.2)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S17.3"></a><a name="section-15.3"></a><p></p>
<h2>17.3     Abnormal <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">Vaginal Bleeding</span></h2>
<p class="First">Inform postmenopausal women of the importance of reporting abnormal <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span> to their healthcare provider as soon as possible <span class="Italics">[see <a href="#S5.3">Warnings and Precautions (5.3)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S17.4"></a><a name="section-15.4"></a><p></p>
<h2>17.4     Possible Serious Adverse Reactions with Estrogen Therapy</h2>
<p class="First">Inform postmenopausal women of possible serious adverse reactions of estrogen therapy including <span class="product-label-link" type="condition" conceptid="134057" conceptname="Disorder of cardiovascular system">Cardiovascular Disorders</span>, Malignant Neoplasms, and Probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">Dementia</span> <span class="Italics">[see <a href="#S5.2">Warnings and Precautions (5.2</a>, <a href="#S5.3">5.3</a>, <a href="#S5.4">5.4)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S17.5"></a><a name="section-15.5"></a><p></p>
<h2>17.5     Possible Less Serious Adverse Reactions with DUAVEE</h2>
<p class="First">Inform postmenopausal women of possible less serious but common adverse reactions of DUAVEE therapy such as <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">muscle spasms</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>, <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">upper abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="26711" conceptname="Chronic pharyngitis">throat pain</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> and <span class="product-label-link" type="condition" conceptid="24134" conceptname="Neck pain">neck pain</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S17.6"></a><a name="section-15.6"></a><p></p>
<h2>17.6     Calcium and Vitamin D Intake</h2>
<p class="First">Advise patients to add supplemental calcium and/or vitamin D to the diet if daily intake is inadequate.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-16"></a><p></p>
<p class="First"><img alt="Logo" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e1b75458-2e5b-46b9-92c6-fa6daba3770f&amp;name=duavee-02.jpg"></p>
<p>LAB-0582-2.0</p>
</div>
<div class="Section" data-sectionCode="42230-3">
<a name="PPI"></a><a name="section-17"></a><p></p>
<h1>Patient Information</h1>
<p class="First"><span class="Bold">DUAVEE<span class="Sup">®</span> (DEW' ah-vee) <br>(conjugated estrogens/bazedoxifene)<br>Tablets</span></p>
<p>Read this Patient Information before you start taking DUAVEE and each time you get a refill. There may be new information. This information does not take the place of talking to your healthcare provider about your medical condition or your treatment.</p>
<table class="Noautorules" width="100%">
<col align="left" valign="top" width="100%">
<tbody class="Headless">
<tr><td class="Lrule Rrule Toprule" align="left"><span class="Bold">What is the most important information I should know about DUAVEE?</span></td></tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left"><ul>
<li>Do not take additional estrogen products while you are taking DUAVEE.</li>
<li>Using estrogens may increase your chance of getting cancer of the uterus (womb).</li>
<li>Report any unusual <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span> right away while you are taking DUAVEE. <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">Vaginal bleeding</span> after <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">menopause</span> may be a warning sign of cancer of the uterus (womb). Your healthcare provider should check any unusual <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span> to find out the cause.</li>
<li>Do not use estrogens to prevent heart disease, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attacks</span>, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">strokes</span> or <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> (decline in brain function).</li>
<li>Using estrogens may increase your chances of getting <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">strokes</span> or blood clots.</li>
<li>Using estrogens may increase your chance of getting <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>, based on a study of women 65 years of age or older.</li>
<li>You and your healthcare provider should talk regularly about whether you still need treatment with DUAVEE.</li>
</ul></td></tr>
</tbody>
</table>
<p><span class="Bold">What is DUAVEE?</span></p>
<p>DUAVEE is a prescription medicine that contains a mixture of estrogens and bazedoxifene.</p>
<p><span class="Bold">What is DUAVEE used for?</span></p>
<p>DUAVEE is used after <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">menopause</span> for women with a uterus to:</p>
<ul class="Disc">
<li>
<span class="Bold">reduce moderate to severe <span class="product-label-link" type="condition" conceptid="4113666" conceptname="Menopausal flushing">hot flushes</span></span><br>Estrogens are hormones made by a woman's ovaries. The ovaries normally stop making estrogens when a woman is between 45 and 55 years old. This drop in body estrogen levels causes the "change of life" or <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">menopause</span> (the end of monthly menstrual periods). Sometimes both ovaries are removed during an operation before natural <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">menopause</span> takes place. The sudden drop in estrogen levels causes "<span class="product-label-link" type="condition" conceptid="440155" conceptname="Postartificial menopausal syndrome">surgical menopause</span>."<br>When the estrogen levels begin dropping, some women get very uncomfortable symptoms, such as feelings of warmth in the face, neck, and chest, or sudden intense episodes of heat and <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span> ("<span class="product-label-link" type="condition" conceptid="4113666" conceptname="Menopausal flushing">hot flashes</span>" or "<span class="product-label-link" type="condition" conceptid="4113666" conceptname="Menopausal flushing">hot flushes</span>"). In some women, the symptoms are mild, and they will not need to take medicines. In other women, symptoms can be more severe.</li>
<li>
<span class="Bold">help reduce your chances of developing <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span> (thin, weak bones)</span><br>If you use DUAVEE only to prevent <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span> due to <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">menopause</span>, talk with your healthcare provider about whether a different treatment or medicine without estrogens might be better for you.<br>DUAVEE should be taken for the shortest time possible and only for as long as treatment is needed.</li>
</ul>
<p>You and your healthcare provider should talk regularly about whether you still need treatment with DUAVEE.</p>
<p>DUAVEE is not for use in children.</p>
<p>It is not known if DUAVEE is safe and effective in people with kidney problems.</p>
<p><span class="Bold">Who should not take DUAVEE?</span></p>
<p><span class="Bold">Do not take DUAVEE if you:</span></p>
<ul>
<li><span class="Bold">currently have or have had blood clots</span></li>
<li>
<span class="Bold">are allergic to estrogens or bazedoxifene, the active ingredients in DUAVEE, or any of its ingredients. </span><br>See the <a href="#ingredients">list of ingredients</a> in DUAVEE at the end of this leaflet.</li>
<li>
<span class="Bold">have unusual <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span>. </span><span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">Vaginal bleeding</span> after <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">menopause</span> may be a warning sign of cancer of the uterus (womb). Your healthcare provider should check any unusual <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span> to find out the cause.</li>
<li>
<span class="Bold">currently have or have had certain cancers. </span>Estrogens may increase the chances of getting certain types of cancers, including cancer of the breast or uterus. If you have or have had cancer, talk with your healthcare provider about whether you should use DUAVEE.</li>
<li><span class="Bold">currently have or have had liver problems </span></li>
<li><span class="Bold">have been diagnosed with a <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> disorder</span></li>
<li>
<span class="Bold">think you may be pregnant. </span>DUAVEE is not for pregnant women. If you think you may be pregnant, you should have a pregnancy test and know the results. Do not take DUAVEE if the test is positive and talk to your healthcare provider.</li>
<li>
<span class="Bold">are breastfeeding or plan to breastfeed. </span>It is not known if DUAVEE passes into your breast milk. You and your healthcare provider should decide if you will take DUAVEE or breastfeed. You should not do both.</li>
</ul>
<p><span class="Bold">What should I tell my healthcare provider before taking DUAVEE?</span></p>
<p><span class="Bold">Before you take DUAVEE, tell your healthcare provider if you:</span></p>
<ul>
<li><span class="Bold">have any unusual <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span>.</span></li>
<li>
<span class="Bold">have any other medical conditions. </span>Your healthcare provider may need to check you more carefully if you have certain conditions, such as <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> (<span class="product-label-link" type="condition" conceptid="314754" conceptname="Wheezing">wheezing</span>), <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> (<span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>), <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>, <span class="product-label-link" type="condition" conceptid="433527" conceptname="Endometriosis">endometriosis</span>, lupus, or problems with your heart, liver, thyroid, kidneys, or have high calcium levels in your blood.</li>
<li>
<span class="Bold">are going to have surgery or will be on bed rest.</span> Your healthcare provider will let you know if you need to stop taking DUAVEE.</li>
</ul>
<p><span class="Bold">Tell your healthcare provider about all the medicines you take, </span>including prescription and over-the-counter medicines, vitamins, and herbal supplements.</p>
<p>Especially tell your healthcare provider if you take other hormonal medicines, including progestins or other medicines like DUAVEE. Ask your healthcare provider if you do not know if you take any of these medicines.</p>
<p>Some medicines may affect how DUAVEE works. DUAVEE may also affect how your other medicines work. Keep a list of your medicines and show it to your healthcare provider and pharmacist when you get a new medicine.</p>
<p><span class="Bold">How should I take DUAVEE?</span></p>
<ul>
<li><span class="Bold">DUAVEE comes in a <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> package.</span></li>
<li><span class="Bold">Record the date you open the foil pouch in the space provided on the <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> package label. Do not use if the <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> package has been open for more than 60 days.</span></li>
<li>Take DUAVEE exactly as your healthcare provider tells you to take it.</li>
<li>Take 1 DUAVEE tablet at the same time each day.</li>
<li>DUAVEE should be swallowed whole.</li>
<li>Take DUAVEE with or without food.</li>
<li>You should not remove DUAVEE from the <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> until right before you are ready to take it. Remove 1 tablet at a time from the <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> package. Do not place DUAVEE in pill boxes or pill organizers.</li>
<li>If you miss a dose of DUAVEE, take it as soon as you remember. If it is almost time for your next dose, skip the missed dose. Take the next dose at your regular time. <span class="Bold">Do not</span> take 2 doses at the same time unless your healthcare provider tells you to. If you are not sure about your dosing, call your healthcare provider.</li>
<li>If you take a calcium or vitamin D supplement, you may take it at the same time you take DUAVEE.</li>
<li>If you take too much DUAVEE, call your healthcare provider. Symptoms of taking too much DUAVEE include:</li>
</ul>
<table class="Noautorules" width="100%">
<col align="left" valign="top" width="2%">
<col align="left" valign="top" width="49%">
<col align="left" valign="top" width="49%">
<tbody class="Headless"><tr>
<td align="left"></td>
<td align="left"><ul class="Circle">
<li><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span></li>
<li><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></li>
<li><span class="product-label-link" type="condition" conceptid="4208409" conceptname="Breast tenderness">breast tenderness</span></li>
<li><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span></li>
</ul></td>
<td align="left"><ul class="Circle">
<li><span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span></li>
<li>feeling tired</li>
<li><span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span></li>
</ul></td>
</tr></tbody>
</table>
<p><span class="Bold">What are the possible side effects of DUAVEE?</span></p>
<p><span class="Bold">Side effects are grouped by how serious they are and how often they happen when you are treated.</span></p>
<p><span class="Bold">Serious side effects include:</span></p>
<ul>
<li>blood clots</li>
<li><span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span></li>
<li><span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span></li>
<li>cancer of the lining of the uterus</li>
<li>breast cancer</li>
<li>cancer of the ovary</li>
<li><span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span></li>
<li>gallbladder problems</li>
<li><span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">loss of vision</span></li>
<li>high blood pressure</li>
<li>increased fats in your blood</li>
<li>liver problems</li>
<li>thyroid problems</li>
<li><span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span></li>
<li>low calcium</li>
<li><span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of your mouth or tongue</li>
<li>worsening of other medical problems such as <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span>, <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraines</span>, a genetic problem called <span class="product-label-link" type="condition" conceptid="4305376" conceptname="Porphyria">porphyria</span>, lupus and liver problems</li>
</ul>
<p><span class="Bold">Call your healthcare provider right away if you get any of the following warning signs, or any other unusual symptoms that concern you:</span></p>
<ul>
<li>new <span class="product-label-link" type="condition" conceptid="80767" conceptname="Breast lump">breast lumps</span></li>
<li>unusual <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span></li>
<li>changes in vision or speech</li>
<li>sudden new severe <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span></li>
<li>severe <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pains</span> in your chest or legs with or without <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> and <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span></li>
</ul>
<p><span class="Bold">Less serious, but common side effects include:</span></p>
<ul>
<li><span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">muscle spasms</span></li>
<li><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span></li>
<li><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span></li>
<li><span class="product-label-link" type="condition" conceptid="4012224" conceptname="Upset stomach">upset stomach</span></li>
<li><span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span></li>
<li><span class="product-label-link" type="condition" conceptid="26711" conceptname="Chronic pharyngitis">throat pain</span></li>
<li><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span></li>
<li><span class="product-label-link" type="condition" conceptid="24134" conceptname="Neck pain">neck pain</span></li>
</ul>
<p>These are not all the possible side effects of DUAVEE. For more information, ask your healthcare provider or pharmacist. Tell your healthcare provider if you have any side effects that bother you or do not go away.</p>
<p>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</p>
<p><span class="Bold">What can I do to lower my chances of a serious side effect with DUAVEE?</span></p>
<ul>
<li>Talk with your healthcare provider regularly about whether you should continue taking DUAVEE.</li>
<li>See you healthcare provider right away if you get <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span> while taking DUAVEE.</li>
<li>Have a pelvic exam, breast exam and mammogram (breast X-ray) every year unless your healthcare provider tells you something else.</li>
<li>If members of your family have had breast cancer or if you have ever had <span class="product-label-link" type="condition" conceptid="80767" conceptname="Breast lump">breast lumps</span> or an abnormal mammogram, you may need to have breast exams more often.</li>
<li>If you have high blood pressure, high <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> (fat in the blood), <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, are overweight, or if you use tobacco, you may have higher chances of getting heart disease.</li>
</ul>
<p>Ask your healthcare provider for ways to lower your chances of getting heart disease.</p>
<p><span class="Bold">How do I store DUAVEE?</span></p>
<ul>
<li>Store DUAVEE at room temperature between 68°F to 77°F (20°C to 25°C).</li>
<li>Keep DUAVEE in the <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> until you are ready to take it to protect the tablet from moisture.</li>
<li>Do not place DUAVEE in pill boxes or pill organizers.</li>
<li>After opening the foil pouch the DUAVEE <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span> come in, DUAVEE must be used within 60 days.</li>
</ul>
<p><span class="Bold">Keep DUAVEE and all other medicines out of the reach of children.</span></p>
<p><span class="Bold">General information about the safe and effective use of DUAVEE</span></p>
<p>Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use DUAVEE for a condition for which it was not prescribed. Do not give DUAVEE to other people, even if they have the same symptoms you have. It may harm them.</p>
<p>This Patient Information summarizes the most important information about DUAVEE. If you would like more information, talk with your healthcare provider. You can ask your pharmacist or healthcare provider for information about DUAVEE that is written for health professionals.</p>
<p>For more information, go to www.DUAVEE.com, or call 1-800-438-1985.</p>
<p><a name="ingredients"></a><span class="Bold">What are the ingredients in DUAVEE?</span></p>
<p><span class="Bold">Active Ingredients</span>: conjugated estrogens and bazedoxifene. Conjugated estrogens are a mixture of sodium estrone sulfate and sodium equilin sulfate and other components, including sodium sulfate conjugates, 17α-dihydroequilin, 17α-estradiol, and 17β-dihydroequilin.</p>
<p><span class="Bold">Inactive Ingredients: </span>calcium phosphate tribasic, hydroxypropyl cellulose, microcrystalline cellulose, powdered cellulose, hypromellose, lactose monohydrate, magnesium stearate, polyethylene glycol, sucrose, ascorbic acid, sucrose palmitic acid ester, hydroxyethylcellulose, titanium dioxide, red iron oxide, yellow iron oxide, black iron oxide, povidone, polydextrose, maltitol, poloxamer 188, propylene glycol, isopropyl alcohol.</p>
<p>This Patient Information has been approved by the U.S. Food and Drug Administration.</p>
<p>This product's label may have been updated. For current full prescribing information, please visit www.pfizer.com.</p>
<p><img alt="Logo" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e1b75458-2e5b-46b9-92c6-fa6daba3770f&amp;name=duavee-02.jpg"></p>
<p>LAB-0583-1.0<br>October 2013</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-18"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 15 Tablet <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blister</span> Card</h1>
<p class="First">NDC 0008-1123-12</p>
<p><span class="Bold Italics">Pfizer</span></p>
<p><span class="Bold"> Duavee</span>™<br>(conjugated estrogens/<br>bazedoxifene)<br>tablets</p>
<p><span class="Bold">per tablet<br>0.45 mg/20 mg*</span></p>
<p><span class="Bold">*Each tablet contains bazedoxifene<br>equivalent to 22.6 mg of<br>bazedoxifene acetate</span></p>
<p>15 tablets</p>
<p>After opening foil pouch, product must be used within 60 days.</p>
<p>Date foil pouch opened:</p>
<p><span class="Bold">Store at 20°C to 25°C (68°F to 77°F); excursions permitted to<br>15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature].</span><br>DOSAGE AND USE: <span class="Bold">See accompanying prescribing information.</span><br>Store product in original package to keep from moisture.<br>Tablets should not be removed from <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span> until immediately<br>before administration. Do not place medication in pill boxes.</p>
<p><span class="Bold">Distributed by<br>Wyeth Pharmaceuticals Inc<br>A subsidiary of Pfizer Inc<br>Philadelphia, PA 19101<br>MADE IN IRELAND</span></p>
<p>Rx only</p>
<p><span class="Bold">PAA042984</span></p>
<p>LOT:</p>
<p>EXP:</p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 15 Tablet <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blister</span> Card" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e1b75458-2e5b-46b9-92c6-fa6daba3770f&amp;name=duavee-03.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-19"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 30 Tablet <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blister</span> Pouch</h1>
<p class="First">NDC 0008-1123-12</p>
<p><span class="Bold Italics">Pfizer</span></p>
<p><span class="Bold"> Duavee</span>™<br>(conjugated estrogens/<br>bazedoxifene)<br>tablets</p>
<p><span class="Bold">0.45 mg/20 mg*</span></p>
<p><span class="Bold">After opening foil pouch, product must be used<br>within 60 days.</span></p>
<p><span class="Bold">Dispense and store product in original package<br>to protect from moisture.</span></p>
<p>30 tablets</p>
<p>Rx only</p>
<p>Package includes 2 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> cards<br>containing 15 tablets each.</p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 30 Tablet <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blister</span> Pouch" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e1b75458-2e5b-46b9-92c6-fa6daba3770f&amp;name=duavee-04.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-20"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 30 Tablet Carton</h1>
<p class="First">NDC 0008-1123-12</p>
<p><span class="Bold Italics">Pfizer</span></p>
<p><span class="Bold"> Duavee</span>™<br>(conjugated estrogens/<br>bazedoxifene)<br>tablets</p>
<p><span class="Bold">0.45 mg/20 mg*</span></p>
<p><span class="Bold">After opening foil pouch, product must be used<br>within 60 days.</span></p>
<p><span class="Bold">Dispense and store product in original package<br>to protect from moisture.</span></p>
<p>Rx only</p>
<p>30 tablets</p>
<p>Package includes 2 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> cards<br>containing 15 tablets each.</p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 30 Tablet Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e1b75458-2e5b-46b9-92c6-fa6daba3770f&amp;name=duavee-05.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>DUAVEE 		
					</strong><br><span class="contentTableReg">conjugated estrogens/bazedoxifene tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0008-1123</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ESTROGENS, CONJUGATED</strong> (ESTROGENS, CONJUGATED) </td>
<td class="formItem">ESTROGENS, CONJUGATED</td>
<td class="formItem">0.45 mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>BAZEDOXIFENE ACETATE</strong> (BAZEDOXIFENE) </td>
<td class="formItem">BAZEDOXIFENE</td>
<td class="formItem">20 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TRIBASIC CALCIUM PHOSPHATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYDROXYPROPYL CELLULOSE (TYPE H)</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POWDERED CELLULOSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYPROMELLOSE 2208 (100000 MPA.S)</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>LACTOSE MONOHYDRATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYETHYLENE GLYCOL 400</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SUCROSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>ASCORBIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SUCROSE PALMITATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYDROXYETHYL CELLULOSE (100 MPA.S AT 2%)</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FERRIC OXIDE RED</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FERRIC OXIDE YELLOW</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FERROSOFERRIC OXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POVIDONES</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYDEXTROSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MALTITOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLOXAMER 188</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>PROPYLENE GLYCOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>ISOPROPYL ALCOHOL</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">PINK (pink) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL (oval) </td>
<td class="formLabel">Size</td>
<td class="formItem">12mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">045;20</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0008-1123-12</td>
<td class="formItem">2  in 1 CARTON</td>
<td class="formItem">10/03/2013</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">15  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA022247</td>
<td class="formItem">10/03/2013</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Wyeth Pharmaceuticals Inc., a subsidiary of Pfizer Inc.
							(828831441)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Pfizer Global Supply - Brandon, a Division of Pfizer Canada Inc.</td>
<td class="formItem"></td>
<td class="formItem">200006526</td>
<td class="formItem">ANALYSIS(0008-1123), API MANUFACTURE(0008-1123)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Wyeth Pharmaceuticals Inc., a subsidiary of Pfizer Inc.</td>
<td class="formItem"></td>
<td class="formItem">828831441</td>
<td class="formItem">ANALYSIS(0008-1123), API MANUFACTURE(0008-1123)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Pfizer Ireland Pharmaceuticals</td>
<td class="formItem"></td>
<td class="formItem">985098505</td>
<td class="formItem">ANALYSIS(0008-1123), LABEL(0008-1123), MANUFACTURE(0008-1123), PACK(0008-1123)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Pfizer Pharmaceuticals LLC</td>
<td class="formItem"></td>
<td class="formItem">829084552</td>
<td class="formItem">LABEL(0008-1123), PACK(0008-1123)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 9/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>e1f39ce6-a8fc-4d12-9aa9-335285af1d1c</div>
<div>Set id: e1b75458-2e5b-46b9-92c6-fa6daba3770f</div>
<div>Version: 6</div>
<div>Effective Time: 20150930</div>
</div>
</div> <div class="DistributorName">Wyeth Pharmaceuticals Inc., a subsidiary of Pfizer Inc.</div></p>
</body></html>
